

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 2003/101444 A1

(51) International Patent Classification⁷: **A61K 31/17**,
31/395, A61P 35/00, C07D 401/12, 213/04, 241/02

(21) International Application Number:
PCT/US2003/016677

(22) International Filing Date: 28 May 2003 (28.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/384,207 29 May 2002 (29.05.2002) US
60/432,796 12 December 2002 (12.12.2002) US

(71) Applicant (*for all designated States except US*): MIL-
LENNIUM PHARMACEUTICALS, INC. [US/US]; 75
Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BOYLE, Robert,
George [GB/GB]; 30 Catharine Street, Cambridge CB1
3AW (GB). IMOGAI, Hassan, Julien [FR/FR]; 30
Teversham Drift, Cambridge CB1 3JX (GB). CHERRY,
Michael [GB/GB]; 20 Lowther Street, Suffolk CB8 OJS
(GB).

(74) Agents: BROOK, David, E. et al.; Hamilton, Brook,
Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box
9133, Concord, MA 01742-9133 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:
26 February 2004

(15) Information about Correction:
see PCT Gazette No. 09/2004 of 26 February 2004, Sec-
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF CAN-
CER

(57) Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.



WO 2003/101444 A1

BEST AVAILABLE COPY

srobertson

WO03101444A1.pdf
10/26/06 12:44 PM



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 03/101444 A1

(51) International Patent Classification⁷: **A61K 31/17**,
31/395, A61P 35/00, C07D 401/12, 213/04, 241/02

(74) Agents: **BROOK, David, E.** et al.; Hamilton, Brook,
Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box
9133, Concord, MA 01742-9133 (US).

(21) International Application Number: PCT/US03/16677

(22) International Filing Date: 28 May 2003 (28.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/384,207 29 May 2002 (29.05.2002) US
60/432,796 12 December 2002 (12.12.2002) US

(71) Applicant (*for all designated States except US*): **MILLE-**
NIUM PHARMACEUTICALS, INC. [US/US]; 75 Sid-
ney Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BOYLE, Robert,**
George [GB/GB]; 30 Catharine Street, Cambridge CB1
3AW (GB). **IMOGAI, Hassan, Julien** [FR/FR]; 30
Teversham Drift, Cambridge CB1 3JX (GB). **CHERRY,**
Michael [GB/GB]; 20 Lowther Street, Suffolk CB8 OJS
(GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF CAN-
CER

(57) Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.



WO 03/101444 A1

DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF
CANCER

5

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.
60/384,207, filed May 29, 2002, and U.S. Provisional Application No. 60/432,796,
10 filed December 12, 2002. The entire teachings of these two applications are
incorporated herein by reference.

BACKGROUND OF THE INVENTION

Cell cycle checkpoints are regulatory pathways that control the order and
15 timing of cell cycle transitions. They ensure that critical events such as DNA
replication and chromosome segregation are completed in high fidelity. The
regulation of these cell cycle checkpoints is a critical determinant of the manner in
which tumor cells respond to many chemotherapies and radiation. Many effective
cancer therapies work by causing DNA damage; however, resistance to these agents
20 remains a significant limitation in the treatment of cancer. Of the several
mechanisms of drug resistance, an important one is attributed to the prevention of
cell cycle progression through the control of critical activation of a checkpoint
pathway. This arrests the cell cycle to provide time for repair, and induces the
transcription of genes to facilitate repair, thereby avoiding immediate cell death. By
25 abrogating checkpoint arrests at, for example, the G2 checkpoint, it may be possible
to synergistically augment tumor cell death induced by DNA damage and


-2-

circumvent resistance. Human Chk-1 plays a role in regulating cell cycle arrest by phosphorylating the phosphatase cdc25 on Serine 216, which may be involved in preventing activation of cdc2/cyclin B and initiating mitosis. Therefore, inhibition of Chk-1 should enhance DNA damaging agents by initiating mitosis before DNA repair is complete and thereby causing tumor cell death.

SUMMARY OF THE INVENTION

It has now been found that certain diaryl ureas are effective inhibitors of Chk-1. For example, the compounds shown in Table 1 of Example 37 have an IC_{50} less than 20 μ mol when tested in an *in vitro* assay that assesses the inhibitory activity of test compounds. It has also been found that phenyl urea CHK-1 inhibitors substituted *ortho* to the urea nitrogen with an -X-NH₂ group, wherein X is an inert linking group, are significantly more effective in enhancing the cytotoxicity of DNA damaging agents than other CHK-1 inhibitors (see Example 38). Linking groups whose length corresponds to the length of -O-(C₂₋₅ alkylidene)- are particularly efficacious. Based on these discoveries, novel Chk-1 inhibitors, methods of inhibiting Chk-1 in a subject and methods of treating cancer are disclosed herein.

One embodiment of the present invention is a method of inhibiting Chk-1 in a subject in need of such treatment. The method comprises administering to the subject an effective amount of a compound of Formula I:



The variables in Formula (I) are defined below.

-3-

X is N or CR¹. In one preferred embodiment, X is C-T-NH₂, C-V-T-NH₂, C-T-NHR^x or C-V-T-NHR^x.

X₁-X₃ are independently CH or N, provided that X₁-X₃ are not all N and X₁ and X₂ are not all N.

5 Z is O, S, or N-CN.

Ring A is optionally substituted at any substitutable carbon by R⁴. Preferably, Ring A is a phenyl ring optionally substituted at any substitutable carbon by R⁴.

R¹ is -H, halogen, T-R⁶ or V-T-R⁶, or R¹ and R² taken together with their intervening atoms form a 5-7 membered ring, preferably a 5-7 membered
 10 heterocycle. When R¹, R² and their intervening carbons together form a heterocycle, preferred values for R¹ and R² together include an optionally substituted methylene, ethylene and propylene. Suitable substituents are as defined below for an alkylidene group. Preferred substituents are =O, C₁₋₃ aliphatic, amine [N(R⁸)₂] and amino alkyl [(CH₂)_qN(R⁸)₂]. Each R⁸ is independently C₁₋₆ alkyl or, taken together with the
 15 nitrogen atom to which they are bonded, is a 5-7 membered nitrogen-containing heterocycle; and q is an integer from 1-6.

T is a C₁₋₆ straight or branched alkylidene chain that is optionally interrupted by -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, or -N(R⁵)SO₂-, wherein the alkylidene chain or a portion thereof is
 20 optionally part of a 3-6 membered ring system.

V is -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, or -N(R⁵)SO₂-.

R² and R³ are each independently selected from hydrogen, C₁₋₆ alkyl optionally substituted with an amine [N(R⁸)₂], -C(=O)R, -CO₂R, or SO₂R, or R² and
 25 R³ taken together with their intervening atoms form an optionally substituted 5-6 membered ring, preferably a 5-6 membered heterocycle. When R², R³ and the intervening carbons together form a 5-6 membered heterocycle, R² and R³ together form, for example, an optionally substituted ethylene, propylene or CH₂NHCH₂. Suitable substituents for the carbon atoms in the groups formed by R² and R³ are as
 30 defined below for an alkylidene group and preferred substituents are =O, C₁₋₃ alkyl, amine [N(R⁸)₂] and amino alkyl [(CH₂)_qN(R⁸)₂]; and suitable substituents for the

nitrogen atom in the groups formed by R^2 and R^3 are as defined below for the nitrogen atom of a heterocycle. R^8 and q are defined above.

Each R^4 is independently selected from halo, -OR, -SR, -CN, -NO₂, -N(R^5)₂, -N(R^5)C(O)R, -N(R^5)CO₂R, -N(R^5)C(O)N(R^5)₂, -C(O)N(R^5)₂, -OC(O)N(R^5)₂, -CO₂R, -SO₂R, -S(O)R, -SO₂N(R^5)₂, -N(R^5)SO₂R, or an optionally substituted group selected from C₁₋₈ aliphatic, aryl, aralkyl, heterocycle, heterocyclealkyl, heteroaryl, or heteroaralkyl. Additionally, R^4 can be -C(O) R^5 .

Additionally, two R^4 's *ortho* to each other, taken together with the carbon atoms of Ring A to which they are bonded, form an optionally substituted five or six membered phenyl, pyridyl or heterocycle fused to Ring A. When two *ortho* R^4 's and the carbon atoms of Ring A to which they are bonded form a heterocycle, the two *ortho* R^4 's, together form, for example, an optionally substituted propylene, butylene, methylene dioxy, ethylene dioxy, O(CH₂)₂ O(CH₂)₃, NH(CH₂)₂ or NH(CH₂)₃. Suitable substituents for the groups formed by two R^4 groups are as described below for heterocycles.

In another alternative, R^1 and an R^4 *ortho* to R^1 , taken together with the carbon atoms of Ring A to which they are bonded, form an optionally substituted five or six membered heterocycle fused to Ring A. When R^1 , an *ortho* R^4 and the carbon atoms of Ring A to which they are bonded together form a heterocycle, R^1 and the *ortho* R^4 taken together form, for example, an optionally substituted propylene, butylene, methylene dioxy, ethylene dioxy, O(CH₂)₂ O(CH₂)₃, NH(CH₂)₂ or NH(CH₂)₃. Suitable substituents are as described below for heterocycles. Preferred substituents are C₁₋₃ alkyl, amine [N(R^8)₂] and amino alkyl [(CH₂)_qN(R^8)₂]. R^8 and q are as described above.

Each R^5 is independently selected from hydrogen, C₁₋₆ aliphatic, -CO₂R, -SO₂R, or -C(O)R, or two R^5 's on the same nitrogen taken together with the nitrogen form a 5-8 membered heteroaryl or heterocycle ring having 1-4 heteroatoms selected from N, O or S.


R^6 is hydrogen, -OR, -N(R)₂, or an optionally substituted 4-14 membered ring system wherein at least one of the ring atoms is a basic nitrogen. Preferred ring

-5-

systems for R^6 include cycloalkyl, heteroaryl and monocyclic heterocyclyls formed from $-N(R)_2$, taken together. Suitable substituents for ring systems represented by R^6 are as described below for aliphatics, heteroaryls and heterocyclyls. Preferred substituents are amine $[N(R^8)_2]$ and amino alkyl $[(CH_2)_qN(R^8)_2]$. R_8 and q are as described above.


R^x is a C1-C8 alkyl group, preferably a C1-C3 alkyl group, more preferably a methyl group.

G is a substituted or unsubstituted aryl or heteraryl group. Preferably, G is Ring B or Ring C.



Ring B is

Y_{1-4} are each independently selected from CH or nitrogen, provided that Ring B has no more than three nitrogen atoms and Y_1 and Y_2 are not both N, said Ring B being optionally substituted by C_{1-4} aliphatic or haloaliphatic, $-OR^7$, $-SR^7$, $-C(O)R^7$, $-CO_2R^7$, $-SO_2R^7$, $-CN$, $-C(O)N(R^7)_2$, $-N(R^7)C(O)(C_{1-2} \text{ alkyl})$, or $-N(R^7)_2$.



Ring C is

E-F-G is O-CH=CH, O-N=CH, CH-O-CH, CH=CH-O, S-CH=CH, or CH-S-CH, said Ring C being optionally substituted by C_{1-4} aliphatic or haloaliphatic, $-OR^7$, $-SR^7$, $-C(O)R^7$, $-CO_2R^7$, $-SO_2R^7$, $-CN$, $-C(O)N(R^7)_2$, $-N(R^7)C(O)(C_{1-2} \text{ alkyl})$, or $-N(R^7)_2$;

Each R^7 is independently selected from hydrogen or an optionally substituted C_{1-3} aliphatic or $-N(R^7)_2$, taken together, is a nitrogen containing heterocyclyl.


Each R^8 and each q in the compound of Formula I is independently selected.

Each R is independently selected from hydrogen or an optionally substituted group selected from C_{1-6} aliphatic, aryl, aralkyl, heteroaryl, or heteroaralkyl.

-6-


Another embodiment of the present invention is a method of treating cancer in a subject. The method comprises administering to the subject an effective amount of a compound of Formula I.

Yet another embodiment of the present invention is a compound of Formula
 5 **II**:

**II**

X, X₁₋₃, Ring A, R and R¹-R⁸ in Formula **II** are as defined for Formula I, provided that R¹ is not *tert*-butyl. Ring **D** in Formula **II** is optionally substituted, as described
 10 above for Ring **B** in Formula I.

Yet another embodiment of the present invention is a compound represented by Structural Formula **III**:

**III**

15

R¹ is -V-T-NH₂, -T-NH₂, -V-T-NHR^x or -T-NHR^x (preferably -V-T-NH₂, -T-NH₂).

X₄ is N or CH. In one preferred embodiment X₄ is CH. In another preferred embodiment, X₄ is N.

20 The remainder of the variables in Formula **III** are as described for Formula **II** above, provided, however, that Ring **D** is optionally substituted and is optionally

fused to an optionally substituted six membered aromatic ring (preferably phenyl) or optionally substituted cyclohexyl ring. R^x is a C1-C8 alkyl group, preferably a C1-C3 alkyl group, more preferably a methyl group. In preferred embodiment, i) X_1 is N and X_2 and X_3 are CH; X_2 is N and X_1 and X_3 are CH; X_3 is N and X_1 and X_2 are CH; X_1 - X_3 are CH; ii) Ring A is optionally substituted at any substitutable carbon by R^4 ; and iii) the remainder of the variables in Formula III are as described above. It is more preferred that X_1 - X_3 are CH; and Ring A optionally is substituted at any substitutable carbon by R^4 .

Yet another embodiment of the present invention is a method of inhibiting Chk-1 in a subject in need of such treatment. The method comprises administering to the subject an effective amount of a compound of Formula III.

Yet another embodiment of the present invention is a method of treating cancer in a subject. The method comprises administering to the subject an effective amount of a compound of Formula III.

Yet another embodiment of the present invention is a pharmaceutical composition comprising a compound of Formula I, II or III and a pharmaceutically effective excipient, carrier or diluent. The pharmaceutical compositions can be used in therapy, e.g., to inhibit CHK-1 activity in a subject in need of such inhibition or to treat a subject with cancer.

Yet another embodiment of the present invention is the use of a compound of Formula I, II or III for the manufacture of a medicament for inhibiting Chk-1 in a subject in need of such inhibition or for treating a subject with cancer.

The compounds disclosed herein are effective inhibitors of Chk-1. They are therefore expected to be effective in treating subjects with cancer and enhancing the effectiveness of many current anti-cancer therapies, including radiation therapy and anti-cancer agents that exert their cytotoxic activity by damaging the genetic material of cancer cells and inhibiting cellular replication. In addition, the disclosed Chk-1 inhibitors, when used in combination with current anti-cancer therapies are expected to be effective against multidrug resistant cancers.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel methods of therapy utilizing the compounds of Formula I or III and to a novel compound of Formula II or III.

In a preferred embodiment, the compound of Formula I has one or more of the following features: (a) R^2 and R^3 are each hydrogen; (b) Z is oxygen; and, (c) G is Ring B; and the compound of Formula II and III has Feature (a) and/or Feature (b). More preferably, the compound of Formula I has Feature (a), Feature (b) and Feature (c); and the compound of Formula II and III has Feature (a) and (b). When the compound of Formula III has the features described in this paragraph, V is preferably -O-; T is preferably a C_{2-5} alkylidene; and the remainder of the variables in Formula III are as described in the "Summary of the Invention".


Alternatively, the compound of Formulas I and II are as described in the previous paragraph, provided that X is C-T-NH₂, C-V-T-NH₂, C-T-NHR^x or C-V-T-NHR^x. More preferably, V is -O- and T is a C_{2-5} alkylidene chain.

In another preferred embodiment, the compound of Formula I and Formula II has Feature (d) wherein R^1 is V-T- R^6 ; V is -O-, T is a C_{2-4} alkylidene chain, R^6 is -OR, -N(R)₂ or a 5-7 membered ring system wherein at least one of the ring atoms is a basic nitrogen, and each R is independently selected from hydrogen or a C_{1-6} aliphatic. More preferably, R^1 is V-T- R^6 wherein V is -O-, T is a C_{2-3} alkylidene chain, R^6 is -OR, -N(R)₂ or a 5-6 membered ring system wherein at least one of the ring atoms is a basic nitrogen, and each R is independently selected from hydrogen or a C_{1-3} aliphatic. Even more preferably, R^1 is V-T- R^6 wherein V is -O-, T is an ethylene or propylene chain, R^6 is -OH, -N(C_{1-2} alkyl)₂, piperidin-1-yl, morpholin-4-yl, 4-substituted-piperazin-1-yl, pyrrol-1-yl, imidazol-1-yl, indol-1-yl, benzimidazol-1-yl, or 9H-carbazol-9-yl.


In a more preferred embodiment the compound of Formula I has Feature (d) and one or more of Features (a), (b) and (c); and the compound of Formula II has Feature (d) and one or more of Features (a) and (b). Even more preferably, the compound of Formula I has Features (a), (b), (c) and (d); and the compound of Formula II has Features (a), (b) and (d).

Alternatively, R^1 in the compounds defined herein is represented by $-X-NH_2$ or $-X-NHR^x$, wherein R^x is as defined above and X is an inert linking group. As used herein, an inert linking group does not significantly diminish the activity of the compound towards Chk-1 and places the NH_2 or NHR^x group at a specific distance from the aromatic group to which the inert linking group is bonded. Examples of inert linking group are provided by T or V-T, as defined above for Formula I. Typically, this specific distance corresponds to the length of an C_{2-5} alkylidene or $-O-C_{2-5}$ alkylidene group.


Another embodiment of the present invention is one of the following compounds and the use thereof for inhibiting Chk-1 in a subject in need of such treatment and for the treatment of cancer, as described herein:




Compound 1




Compound 2




Compound 3




Compound 4




Compound 5




Compound 6




Compound 7




Compound 8




Compound 9



Compound 10




Compound 11




Compound 12


-10-




Compound 13




Compound 14




Compound 15




Compound 16




Compound 17




Compound 18




Compound 19




Compound 20




Compound 21




Compound 22




Compound 23




Compound 24



Compound 25




Compound 26




Compound 27


-11-




Compound 28




Compound 29




Compound 30




Compound 31




Compound 32




Compound 33




Compound 34




Compound 35




Compound 36



Compound 37




Compound 38




Compound 39

10


-12-




Compound 40




Compound 41




Compound 42




Compound 43




Compound 44




Compound 45




Compound 46




Compound 47




Compound 48



Compound 49



Compound 50




Compound 51

5


10

15


-13-




Compound 52




Compound 53




Compound 54




Compound 55




Compound 56




Compound 57




Compound 58




Compound 59




Compound 60



c Compound 61




Compound 62




Compound 63

10


-14-




Compound 64




Compound 65




Compound 66



Compound 67




Compound 68




Compound 69


5




Compound 70




Compound 71




Compound 72



Compound 73




Compound 74




Compound 75

10


-15-




Compound 76




Compound 77




Compound 78




Compound 79




Compound 80




Compound 81




Compound 82




Compound 83




Compound 84



Compound 85




Compound 86




Compound 89

5


10




Compound 90




Compound 91




Compound 92




Compound 92




Compound 93




Compound 94




Compound 95




Compound 96




Compound 97



Compound 98




Compound 99




Compound 100


-17-




Compound 101




Compound 102




Compound 103




Compound 104




Compound 105



Compound 106




Compound 107




Compound 108

10


-18-




Compound 109



Compound 110



Compound 111



Compound 112

5

Another embodiment of the present invention is the use of a compound of Formula I for treating cancer or inhibiting Chk-1, as described herein, wherein Ring A has the value of the group at the corresponding position of any one of Compounds 1-112. Preferably, R² and R³ are hydrogen and X is =O.

Another embodiment of the present invention is the use of a compound of Formula I for treating cancer or inhibiting Chk-1, as described herein, wherein G has the value of the group at the corresponding position of any one of Compounds 1-112. Preferably, R² and R³ are hydrogen and X is =O.

Another embodiment of the present invention is a compound of Formula I wherein Ring A has the value of the group at the corresponding position of any one of Compounds 1-112. Preferably, R² and R³ are hydrogen and X is =O.

Another embodiment of the present invention is a compound of Formula I wherein G has the value of the group at the corresponding position of any one of Compounds 1-112. Preferably, R² and R³ are hydrogen and X is =O.

The term "aliphatic" as used herein means straight-chain, branched or cyclic hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic. When straight chained or branched, an

20

aliphatic group is typically C₁₋₈, more typically C₁₋₆; when cyclic, an aliphatic group is typically C₃₋₁₀, more typically C₃₋₇. For example, suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl) alkyl, (cycloalkenyl) alkyl or (cycloalkyl) alkenyl. The terms "alkyl", "alkoxy", "hydroxyalkyl", "alkoxyalkyl", and "alkoxycarbonyl", used alone or as part of a larger moiety includes both straight and branched saturated chains containing one to eight carbon atoms. The terms "alkenyl" and "alkynyl" used alone or as part of a larger moiety shall include both straight and branched chains containing two to eight carbon atoms and one or more double or triple bonds, respectively. The term "cycloaliphatic" used alone or as part of a larger moiety shall include cyclic C₃₋₁₀ hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic. A "cycloalkyl" is an cyclic aliphatic group that is completely saturated.

The terms "haloaliphatic", "haloalkyl", "haloalkenyl" and "haloalkoxy" means aliphatic, alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br or I.

The term "heteroatom" means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also the term "nitrogen" includes a substitutable nitrogen of a heterocyclic ring. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in N-substituted pyrrolidinyl).

The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to aromatic ring groups, typically having five to fourteen members, such as phenyl, benzyl, phenethyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. The term "aryl" also refers to rings that are optionally substituted. The term "aryl" may be used interchangeably with the term "aryl ring". "Aryl" also includes fused polycyclic aromatic ring systems in which an aromatic ring is fused to one or more rings. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. Also included within the scope of the term "aryl", as it is used herein, is a group in which an aromatic ring is fused to one or more non-

aromatic rings, such as in an indanyl, phenantriidiny, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.

The term "heterocycle", "heterocyclyl", or "heterocyclic", used alone or as part of a larger moiety as in "heterocyclalkyl", refers to non-aromatic ring systems typically having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S. Examples of heterocyclic rings include 3-1H-benzimidazol-2-one, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [1,3]-dioxalanyl, [1,3]-dithiolanyl, [1,3]-dioxanyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl, diazolonyl, N-substituted diazolonyl, 1-phthalimidinyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl, and benzothianyl. Also included within the scope of the term "heterocyclyl" or "heterocyclic", as it is used herein, is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring. The term "heterocycle", "heterocyclyl", or "heterocyclic" whether saturated or partially unsaturated, also refers to rings that are optionally substituted.

The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to heteroaromatic ring groups having five to fourteen members. Examples of heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl, carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzooxazolyl,

benzimidazolyl, isoquinolinyl, indolyl, isoindolyl, acridinyl, or benzoisazolyl. Also included within the scope of the term “heteroaryl”, as it is used herein, is a group in which a heteroatomic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples
 5 include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido [3, 4-d] pyrimidinyl. The term “heteroaryl” also refers to rings that are optionally substituted. The term “heteroaryl” may be interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.

An “aralkyl”, “heteroaralkyl” and “heterocyclalkyl” is an alkyl group,
 10 typically a C₁₋₈ alkyl group, substituted with an aryl group (preferably a phenyl group), heteroaryl and heterocycl, respectively.

An “alkylidene chain” is a polymethylene group, i.e., -(CH₂)_n-, wherein n is a positive integer. Preferably, n is an integer from 1 to 6, more preferably from 2 to 4 and more preferably from 2 to 3. A “substituted alkylidene chain” is an alkylidene in
 15 which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents are as described below for a substituted aliphatic group.

An alkylidene chain can be optionally interrupted by a functional group. An alkylidene chain is interrupted by a functional group when one of the methylenes is replaced with the functional group. Examples of suitable “interrupting functional
 20 groups” include -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, and -N(R⁵)SO₂-. R⁵ is as described above. Examples of alkylidene chains which have been “interrupted” with -O- include -O-, -O(CH₂)-, -O(CH₂)₂-, -O(CH₂)₃-, -O(CH₂)₄-, -O(CH₂)₅-, -CH₂O-, -CH₂O(CH₂)-, -CH₂O(CH₂)₂-, -CH₂O(CH₂)₃-, -CH₂O(CH₂)₄-, -(CH₂)₂O-, -(CH₂)₂O(CH₂)-, -(CH₂)₂O(CH₂)₂-,
 25 -(CH₂)₂O(CH₂)₃-, -(CH₂)₃O-, -(CH₂)₃O(CH₂)-, -(CH₂)₃O(CH₂)₂-, -(CH₂)₄O-, -(CH₂)₄O(CH₂)- and -(CH₂)₅O-. Other examples of alkylidene chains which have been “interrupted” with functional groups include -M(CH₂)-, -M(CH₂)₂-, -M(CH₂)₃-, -M(CH₂)₄-, -M(CH₂)₅-, -CH₂M-, -CH₂M(CH₂)-, -CH₂M(CH₂)₂-, -CH₂M(CH₂)₃-, -CH₂M(CH₂)₄-, -(CH₂)₂M-, -(CH₂)₂M(CH₂)-, -(CH₂)₂M(CH₂)₂-, -(CH₂)₂M(CH₂)₃-,
 30 -(CH₂)₃M-, -(CH₂)₃M(CH₂)-, -(CH₂)₃M(CH₂)₂-, -(CH₂)₄M-, -(CH₂)₄M(CH₂)- and -(CH₂)₅O-, wherein M is one of the “interrupting” functional groups listed above.

An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Examples of suitable substituents on an unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group include a halogen $-R^0$, $-OR^0$, $-SR^0$, 1,2-methylene-dioxy, 1,2-ethylenedioxy, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, $-O(Ph)$, substituted $-O(Ph)$, $-CH_2(Ph)$, substituted $-CH_2(Ph)$, $-CH_2CH_2(Ph)$, substituted $-CH_2CH_2(Ph)$, $-NO_2$, $-CN$, $-N(R')_2$, $-NR'CO_2R^0$, $-NR'C(O)R^0$, $-NR'NR'C(O)R^0$, $-N(R')C(O)N(R')_2$, $-NR'NR'C(O)N(R')_2$, $-NR'NR'CO_2R^0$, $-C(O)C(O)R^0$, $-C(O)CH_2C(O)R^0$, $-CO_2R^0$, $-C(O)R^0$, $-C(O)N(R^0)_2$, $-OC(O)N(R^0)_2$, $-S(O)_2R^0$, $-SO_2N(R')_2$, $-S(O)R^0$, $-NR'SO_2N(R')_2$, $-NR'SO_2R^0$, $-C(=S)N(R')_2$, $-(CH_2)_yNR'$, $-C(=NH)-N(R')_2$, $-(CH_2)_yNHC(O)R^0$, $-(CH_2)_yNHC(O)CH(V-R^0)(R^0)$. R' is R^0 , $-CO_2R^0$, $-SO_2R^0$ or $-C(O)R^0$ and preferably hydrogen, C_{1-6} aliphatic, CO_2R^0 , SO_2R^0 or $C(O)R^0$. R^0 is hydrogen or substituted or unsubstituted aliphatic, aryl, aralkyl, heterocyclyl, heterocyclalkyl or heteroaryl and preferably hydrogen, C_{1-6} alkyl, phenyl (Ph), $-CH_2(Ph)$, aralkyl, heterocyclyl, heterocyclalkyl or heteroaryl; y is 0-6; and V is a linker group. Examples of substituents on the aliphatic group or the phenyl ring of R^0 include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, aminoalkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl. Preferred substituents for Ring A are substituents represented by R^4 ; and preferred substituents for Rings B and C are C_{1-4} aliphatic or haloaliphatic, $-OR^7$, $-SR^7$, $-C(O)R^7$, $-CO_2R^7$, $-SO_2R^7$, $-CN$, $-C(O)N(R^7)_2$, $-N(R^7)C(O)(C_{1-2} \text{ alkyl})$, or $-N(R^7)_2$, wherein R^7 is as defined above.

Certain particularly preferred substituents for Ring B are $-CN$, $-COOR^7$ and $-CON(R^7)_2$ at the position

para to the carbon bonded to the urea nitrogen. These substituents are even more preferred when Ring B is pyridine.

An aliphatic group or a heterocycle may contain one or more substituents. Examples of suitable substituents on the saturated carbon of an aliphatic group of a

heterocycle include those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: =O, =S, =NNHR*, =NN(R*)₂, =NNHC(O)R*, =NNHCO₂ (alkyl), =NNHSO₂ (alkyl), or =NR*. Each R* is independently selected from hydrogen, an unsubstituted aliphatic group or a substituted aliphatic group.

5 Examples of substituents on the aliphatic group represented by R* include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.

10 Suitable substituents on the nitrogen of a heterocycle include -R⁺, -N(R⁺)₂, -C(O)R⁺, -CO₂ R⁺, -C(O)C(O)R⁺, -C(O)CH₂ C(O)R⁺, -SO₂ R⁺, -SO₂ N(R⁺)₂, -C(=S)N(R⁺)₂, -C(=NH)-N(R⁺)₂, and -NR⁺ SO₂ R⁺; wherein R⁺ is hydrogen, an aliphatic group, a substituted aliphatic group, phenyl (Ph), substituted Ph, -O(Ph), substituted -O(Ph), CH₂(Ph), or an unsubstituted heteroaryl or heterocyclic ring.

15 Examples of substituents on the aliphatic group or the phenyl ring represented by R⁺ include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.

As noted above, Ring A of Formula III is optionally substituted with one or
 20 more groups R⁴ and Ring D of Formula III is optionally substituted with C₁₋₄ aliphatic, C₁₋₄ haloaliphatic, -OR⁷, -SR⁷, -C(O)R⁷, -CO₂R⁷, -SO₂R⁷, -CN, -C(O)N(R⁷)₂, -N(R⁷)C(O)(C₁₋₂ alkyl) or -N(R⁷)₂ and is optionally fused to a six membered aromatic ring (preferably phenyl) or cyclohexyl ring. R⁴ and R⁷ are as described above and the fused six membered or cyclohexyl ring are optionally
 25 substituted. Preferably, at least one R⁴ is *para* to the carbon bonded with R¹ and Ring D, is optionally substituted *meta* and/or *para* to the carbon bonded with the urea nitrogen. More preferably Ring A is monosubstituted *para* to the carbon bonded with the R¹ and Ring D is optionally monosubstituted *meta* or *para* to the carbon bonded with the urea nitrogen. Preferred values for R⁴ are -F, -Cl, -Br, -I, -COOR^a,
 30 -NHCOR^a, -CF₃, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -N(R^a)₂, -CH₂N(R^a)₂, -CH₂CH₂N(R^a)₂, piperidinyl, morpholinyl and pyrrolidinyl, wherein R^a is -CH₃,

-CH₂CH₃, -CH₂CH₂NH₂, -CH₂CH₂NH(CH₃), -CH₂CH₂N(CH₃)₂, -CH₂CH₂(*N*-morpholinyl), -CH₂CH₂(*N*-piperidinyl) or -CH₂CH₂(*N*-pyrrolidinyl). Preferred substituents for Ring **D** of Formula **III** include methyl, -OCH₃, -NH₂, phenyl fused to Ring **D** or cyclohexyl fused to Ring **D**. Suitable substituents for a cyclohexyl or
5 six membered aromatic ring fused to Ring **D** are as described above for aliphatic and aryl ring substituents. Preferred substituents for these fused rings include methoxy, methyl, halogen, nitro and cyano. Other preferred substituents for Ring **D** include -CO₂R⁷, -CN or -C(O)N(R⁷)₂ at the position *para* to the carbon atom bonded to the urea nitrogen.

10 Additionally, pharmaceutically acceptable salts of the compounds of Formula **I**, **II** and **III** are included in the present invention. For example, an acid salt of a compound containing an amine or other basic group can be obtained, by reacting the compound with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a
15 quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino
20 acids such as glutamic acid.

Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base. Such a pharmaceutically acceptable salt may be made with a base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline
25 earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, *N,N'*-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, *N*-
30 benzyl- β -phenethylamine, dehydroabietylamine, *N,N'*-bisdehydroabietylamine,

glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine.

The disclosed Chk-1 inhibitors are advantageously administered to inhibit Chk-1 in a subject in whom a beneficial therapeutic or prophylactic effect can be achieved by inhibiting Chk-1, i.e., a subject in need of Chk-1 inhibition. A “subject” is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).

Chk-1 inhibition can be used to achieve a beneficial therapeutic or prophylactic effect, for example, in subjects with cancer. Cancers which can be treated with Chk-1 inhibitors include cancers or cell types (e.g., solid tumors such as colon, breast, lung, ovarian, pancreatic or non-solid tumors such as non-Hodgkins lymphomas and leukemias) in which p53 or the p53 pathway has been inactivated or abrogated. Chk-1 inhibitors are particularly useful in the treatment of cancers or cell types in which Chk1 protein or activity is up regulated (e.g., retinoblastomas such as Rb negative or inactivated cells or where the ARF^{p14/p19} locus has been inactivated or misregulated. Use of Chk-1 inhibitors as drugs for the treatment of cancer is particularly advantageous and can enhance the effectiveness of the treatment when:

1) combined with radiation therapy or with an anti-cancer drugs which act by causing damage to the genetic material of cells (referred to herein as “DNA damaging anti-cancer drugs”); 2) combined with agents which are otherwise cytotoxic to cancer cells during cell division; 3) combined with agents which are proteasome inhibitors; 4) combined with agents which inhibit NF- κ B (e.g., IKK inhibitors); or 5) used with combinations of cancer drugs with which are not cytotoxic when administered alone, yet in combination produce a toxic effect.

Examples of DNA damaging anti-cancer drugs include Topoisomerase I inhibitors (e.g., irinotecan, camptothecin and analogs or metabolites thereof and doxorubicin); Topoisomerase II inhibitors (e.g., etoposide and daunorubicin); alkylating agents (e.g., methotrexate or cyclophosphamide); DNA intercalators (e.g., cisplatin and carboplatin); DNA intercalators and free radical generators such as bleomycin; and

-26-

nucleoside mimetics (e.g., 5-fluorouracil gemcitabine and hydroxyurea). Agents which disrupt cell replication include: taxol, taxol analogs vinblastin and vinblastin analogs); antibodies such as Trastuzumab (Herceptin) which bind to proteins overexpressed in cancers and thereby downregulate cell replication; and inhibitors
5 such as STI-571 (e.g., Gleevec) of proteins or enzymes known to be upregulated, over-expressed or activated in cancers, the inhibition of which downregulates cell replication.

The disclosed Chk-1 inhibitors are also effective when used in combination with DNA-damaging anti-cancer drugs and/or radiation therapy to treat subjects with
10 multi-drug resistant cancers. A cancer is resistant to a drug when it resumes a normal rate of tumor growth while undergoing treatment with the drug after the tumor had initially responded to the drug. A tumor “responds to a drug” when it exhibits a decrease in tumor mass or a decrease in the rate of tumor growth. The term “multi-drug resistant cancer” refers to cancer that is resistant to two or more drugs, typically
15 five or more.

As such, an “effective amount” of the disclosed Chk-1 inhibitors is the quantity which inhibits Chk-1 when administered to a subject or which, when administered to a subject with cancer, slows tumor growth, ameliorates the symptoms of the disease and/or increases longevity. When used in combination with
20 radiation therapy, with a DNA-damaging drug or other anti-cancer drug, an effective amount of the Chk-1 inhibitor is the quantity in which a greater response is achieved when the Chk-1 inhibitor is co-administered with the DNA damaging anti-cancer drug and/or radiation therapy compared with when the DNA damaging anti-cancer drug and/or radiation therapy is administered alone. When used as a combination
25 therapy, an “effective amount” of the DNA damaging drug and/or an “effective” radiation dose are administered to the subject, which is a quantity in which anti-cancer effects are normally achieved. The disclosed Chk-1 inhibitors and the DNA damaging anti-cancer drug can be co-administered to the subject as part of the same pharmaceutical composition or, alternatively, as separate pharmaceutical
30 compositions. When administered as separate pharmaceutical compositions, the disclosed Chk-1 inhibitors and the DNA-damaging anti-cancer drug (and/or

-27-

radiation therapy) can be administered simultaneously or at different times, provided that the enhancing effect of the Chk-1 inhibitor is retained.

The amount of Chk-1 inhibitor, DNA damaging anti-cancer drug and radiation dose administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective dosages for commonly used anti-cancer drugs and radiation therapy are well known to the skilled person. Effective amounts of the disclosed Chk-1 inhibitors typically range between about 1 mg/mm² per day and about 10 grams/mm² per day, and preferably between 10 mg/mm² per day and about 5 grams/mm².

The Chk-1 inhibitors described herein, and the pharmaceutically acceptable salts, solvates and hydrates thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The Chk-1 inhibitor will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in *Remington: the Science and Practice of Pharmacy*, 19th edition, Mack Publishing Co., Easton, PA (1995).

For oral administration, the Chk-1 inhibitor or salts thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like.

The tablets, pills, capsules, and the like contain from about 1 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring
5 such as cherry or orange flavor.

For parental administration the disclosed Chk-1 inhibitor, or salts thereof can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble
10 pharmaceutically-acceptable salts of the compounds. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.


In addition, to the formulations described previously, the compounds may
15 also be formulated as a depot preparation. Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection. Thus, for example, as an emulsion in an acceptable oil, or ion exchange resins, or as sparingly soluble derivatives, for example, as sparingly soluble salts.

20 Preferably disclosed Chk-1 inhibitors or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal. The unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an IV bag, a tablet, or a vial. The quantity of active ingredient (viz., a compound of Structural Formula I, II or III or salts thereof)
25 in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration which may be by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous,
30 intravenous, intramuscular, intraperitoneal and intranasal.

-29-

A synthesis for the preparation of the Chk-1 inhibitors disclosed herein is shown below in the Synthetic Scheme. Specific conditions for carrying out these reactions are provided in Examples 1-28.

Synthetic Scheme




The invention is illustrated by the following examples, which are not intended to be limiting in any way.

EXEMPLIFICATION


Example 1

10 1-[5-Chloro-2-(3-dimethylamino-propoxy)-phenyl]-3-pyrazin-2-yl-urea



The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.6(s, 1H, broad) ; 10.39(s, 1H) ; 8.71(s, 1H) ; 8.31(d, 1H, J=2.2) ; 8.30(dd, 1H, J=2.7, 1.6) ; 8.27(d, 1H, J=2.7) ; 7.06(d, 1H, J=8.6) ; 7.02(dd, 1H, J=8.6, 2.2) ; 4.10(t, 2H, J=6.2) ; 2.40(t, 2H, J=7.1) ; 2.19(s, 6H) ; 1.96(td, 2H, J=7.1, 6.2). LCMS: method A, RT= 2.55min, [MH⁺=350, MNa⁺=373].

-30-

Example 2**1-[5-Chloro-2-(2-dimethylamino-ethoxy)-phenyl]-3-pyrazin-2-yl-urea****Step 1****5 5-Chloro-2-(2-dimethylamino-ethoxy)-phenylamine**

To a suspension of 2-Amino-4-chloro-phenol (1.43g, 10mmoles, 1eq) and potassium carbonate (6.9g, 50mmoles, 5eq) in acetone (25ml) was added in one portion (2-Chloro-ethyl)-dimethyl-amine.hydrochloride (2.16g, 15mmoles, 1.5eq). The reaction mixture was refluxed under Nitrogen for 6 hours at which time the suspension was filtered and the solid washed with acetone. The combined filtrate was concentrated under vacuum and purified by flash chromatography (EtOAc/MeOH/NEt₃: 87/9/3) to afford a beige solid (1.6g, yield= 72%).

¹H NMR (400 MHz, DMSO-d₆) δ 6.78(d, 1H, J=8.6); 6.63(d, 1H, J=2.5); 6.47(dd, 1H, J=8.6, 2.5); 5.03(s, 2H, broad); 3.88(t, 2H, J=5.8); 2.60(t, 2H, J=5.8); 2.21(s, 6H). LCMS: method A, RT=0.5min, [MH⁺=215].


Step 2**Pyrazine-2-carbonyl azide**

To a solution of Pyrazine-2-carboxylic acid (295mg, 2.1mmol, 1eq) and triethylamine (765ul, 5.4mmol, 2.6eq) in THF (6ml) at 0° C was added dropwise diphenylphosphoryl azide(1.4ml, 2.8mmol, 1.3eq). The mixture was stirred under nitrogen at 0° C for 30 minutes, then warmed to RT and stirring continued for a further 2 hours. The reaction mixture was concentrated under vacuum and purified by flash chromatography (90/10-60/40 *Iso*-hexane/EtOAc) to afford the title compound as white solid (265mg, yield=78%). ¹H NMR (400 MHz, CDCl₃) δ 9.14(d, 1H, J=1.2); 8.50(dt, 1H, J=1.2, 0.4), 2.62(s, 3H, broad).

-31-


Step 3**1-[5-Chloro-2-(2-dimethylamino-ethoxy)-phenyl]-3-pyrazin-2-yl-urea**

In the appropriate vial, a solution of Pyrazine-2-carbonyl azide in DCM was irradiated at 110⁰ C for 5 minutes in the Personal Smith Synthesiser. The addition of
 5 a solution of 5-Chloro-2-(2-dimethylamino-ethoxy)-phenylamine (1,2 eq) in DCM followed and the reaction mixture irradiated at 110⁰ C for a further 5 minutes. The desired urea precipitate from the reaction mixture was filtrated and washed with DCM (3x150ml) and ether (3x150ml) to yield a white solid. (yield = 83%) NMR (DMSO-d6) δ 10.6(s, 1H, broad); 10.39(s, 1H); 8.71(s, 1H, broad); 8.3(d, 1H, J=2.2);
 10 8.29(dd, 1H, J=2.7, 1.6), 8.26(d, 1H, J=2.7), 7.05(d, 1H, J=8.6), 7.02(dd, 1H, J=8.6, 2.2), 4.10(t, 2H, J=6.2), 2.40(t, 2H, J=6.2), 2.19(s, 6H). LCMS: method A, RT=2.5min, [MH⁺=336].


Example 3**15 1-[5-Chloro-2-(2-dimethylamino-ethoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea**

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d6) δ 10.25(s, 1H, broad); 10.23(s, 1H); 8.67(s, 1H, broad); 8.29(d, 1H, J=2.6); 8.19(m, 1H) 7.10(d, 1H, J=8.7); 7.02(dd, 1H, J=8.7, 2.6), 4.16(t, 2H, J=6), 2.74(t, 2H, J=6), 2.43(s, 3H), 2.22(s,
 20 6H). LCMS: method A, RT=0.5min and 2.16min, [MH⁺=350].

-32-


Example 4**1-(5-Chloro-2,4-dimethoxy-phenyl)-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure
5 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.08(s, 1H,); 9.99(s, 1H, broad); 8.87(s,1H); 8.32(dd, 1H, J=2.7, 1.6), 8.25(d, 1H, J=2.7); 8.19 (s, 1H); 6.89(s, 1H); 3.96(s, 3H); 3.96(s, 3H). LCMS: method A, RT=2.81min, [MH⁺=309].


10 Example 5**1-[5-Chloro-2-(2-morpholin-4-yl-ethoxy)-phenyl]-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure
15 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.4(s, 1H, broad) ; 10.38(s, 1H) ; 8.77(s,1H) ; 8.31(dd, 1H, J=2.74,1.5) ; 8.29(d, 1H, J=2.7,) ; 8.28(d, 1H, J=2.7) ; 7.12(d, 1H, J=8.6) ; 7.03(dd, 1H, J=8.6, 2.7) ; 4.22(t, 2H, J=6.0) ; 3.53(t, 4H, J=4.4) ; 2.81(t, 2H, J=6.0) ; 3.53(t, 4H, J=4.2). LCMS: method B, RT=3.52min, [MH⁺=377].


-33-

Example 6**1-(5-Chloro-2-methoxy-phenyl)-3-pyrazin-2-yl-urea**


The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.31(s, 1.5H, broad); 8.96(s, 1H,); 8.42(dd, 1H, J=2.5, 1.5); 8.34(d, 2H, J=2.5); 7.15(d, 1H, J=8.5); 7.12 (dd, 1H, J=8.5, 2.2); 3.99(s, 3H).). LCMS: method A, RT= 2.89min, [MH⁺=279].

Example 7**1-[5-Chloro-2-(3-methyl-butoxy)-phenyl]-3-pyrazin-2-yl-urea**


The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.5(s, 1H, broad); 10.39(s, 1H); 8.74(s, 1H); 8.29(d, 1H, J=2.6); 8.28(d, 1H, J=2.7), 8.24(dd, 1H, J=2.7, 1.5), 7.10(d, 1H, J=8.6); 7.03(dd, 1H, J=8.6, 2.6); 4.10(t, 2H, J=6.5); 1.88-1.78(m, 1H), 1.73(td, 2H, J=6.6); 0.94(d, 6H, J=6.4). LCMS: method A, RT= 3.61min, [MH⁺=335].

Example 8**1-(2-Methoxy-5-methyl-phenyl)-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.09(s, 1H, broad) ; 9.99(s, 1H, broad) ; 8.89(s, 1H,); 8.325(dd,1H,J=2.7, 1.6) ; 8.23(d, 1H, J=2.7) ; 8.02(d, 1H, J=2) ; 6.92(d, 1H, J=8.5) ; 6.80 (ddt, 1H, J=8.5, 2.2, 0.6) ; 3.86(s, 3H) ; 2.25(s, 3H). LCMS: method A, RT= 2.8min, [MH⁺=259].

Example 9**1-Pyrazin-2-yl-3-(2-trifluoromethoxy-phenyl)-urea**

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.3(s, 1H, broad) ; 10.12(s, 1H) ; 8.64(s, 1H); 8.17(d, 1H, J=8.3) ; 8.09(d, 1H, J=2.7) ; 8.07 (dd,1H, J=2.7, 1.2) ; 7.24(d, 1H, J=8.3) ; 7.20 (ddd, 1H, J=8.4, 8.4, 1.2) ; 6.97 (ddd, 1H). LCMS: method A, RT= 2.98min, [MH⁺=299].


Example 10**1-(5-Chloro-2-methyl-phenyl)-3-pyrazin-2-yl-urea**

-35-

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.03(s, 1H); 9.69(s, 1H, broad); 8.75(s, 1H); 8.20(dd, 1H, J=2.7, 1.6); 8.14(d, 1H, J=2.7); 8.02-8.012(m, 1H); 7.12(d, 1H, J=8.0); 6.91 (dd, 1H, J=8.5, 2.7); 2.15(s, 3H). LCMS: method B, RT=3.38min, [MH⁺=263].

Example 11


N-[4-Methoxy-3-(3-pyrazin-2-yl-ureido)-phenyl]-acetamide




The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.14(s, 1H); 10.04(s, 1H, broad); 9.83(s, 1H); 8.89(s, 1H); 8.33(dd, 1H, J=2.7, 1.5); 8.27(d, 1H, J=2.4); 8.24(d, 1H, J=2.7); 7.44(dd, 1H, J=8.9, 2.6); 6.95 (d, 1H, J=8.9); 3.87(s, 3H); 2.0(s, 3H). LCMS: method A, RT= 2.38min, [MH⁺=302].

Example 12

4-Methoxy-3-(3-pyrazin-2-yl-ureido)-benzoic acid methyl ester




The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.19(s, 2H); 8.91(s, 1H); 8.84(d, 1H, J=2.2); 8.35(dd, 1H, J=2.7, 1.6); 8.26(d, 1H, J=2.7); 7.68(dd, 1H, J=8.6, 2.1); 7.17 (d, 1H, J=8.6); 4.0(s, 3H); 3.83(s, 3H). LCMS: method A, RT= 3.00min, [MH⁺=303].

Example 131-(2-Methoxy-5-trifluoromethyl-phenyl)-3-pyrazin-2-yl-urea


- 5 The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.30(s, 1H, broad); 10.25(s, 1H); 8.91(s, 1H); 8.58(d, 1H, J=2.2); 8.35(dd, 1H, J=2.6, 1.6); 8.27(d, 1H, J=2.7); 7.39(dd, 1H, J=8.6, 2.1); 7.24 (d, 1H, J=8.6); 4.0(s, 3H). LCMS: method B, RT=3.52min, [MH⁺=213].

10


Example 141-(2,4-Dimethoxy-phenyl)-3-pyrazin-2-yl-urea

- 15 The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.96(s, 1H); 9.78(s, 1H, broad); 8.88(d, 1H, J=1.2); 8.30(dd, 1H, J=2.7, 1.2); 8.22(d, 1H, J=2.7); 7.98(d, 1H, J=8.8); 6.64(d, 1H, J=2.7); 6.5 (dd, 1H, J=8.6, 2.7); 3.88(s, 3H); 3.74(s, 3H). LCMS: method A, RT= 3.47, [MH⁺=243].

20


Example 151-(2-Chloro-5-methoxy-phenyl)-3-pyrazin-2-yl-urea

The title compound was prepared from the appropriate reagents, using a procedure
5 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.39(s, 1H, broad); 10.33(s, 1H); 8.83(s, 1H); 8.34(dd, 1H, J=2.6, 1.5); 8.27(d, 1H, J=2.6); 7.94(d, 1H, J=2.9); 7.40(d, 1H, J=8.9); 6.69(dd, 1H, J=8.9, 2.9); 3.76(s, 3H). LCMS: method A, RT= 2.88, [MH⁺=279].


10 Example 161-(5-Chloro-2-methoxy-phenyl)-3-pyrimidin-4-yl-urea

The title compound was prepared from the appropriate reagents, using a procedure
similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.58(s, 1H, broad); 10.36(s, 1H); 8.86(d, 1H, J=1.1); 8.56(d, 1H, J=5.8); 8.25(dd, 1H, J=1.1, 1.5);
15 7.48(d, 1H, J=5.5); 7.17-7.09(m, 2H); 3.92(s, 3H). LCMS: method A, RT= 2.79, [MH⁺=279].

-38-


Example 171-(2-Methoxy-phenyl)-3-pyrazin-2-yl-urea

The title compound was prepared from the appropriate reagents, using a procedure
5 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.98(s, 1H);
9.90(s, 1H, broad); 8.75(s, 1H); 8.19 (dd, 1H, J=2.5, 1.5) ; 8.10(d, 1H, J=2.5) ; 8.03
(dd, 1H, J=7.3, 1.1); 6.91 (dd, 1H, J=8.0, 1.5) ; 6.87 (ddd, 1H, J=8.0, 7.3, 1.5); 6.78
(ddd, 1H, J=8.0, 7.3, 1.5); 3.76(s, 3H). LCMS: method B, RT= 3.16, [MH⁺=245].


Example 181-(3-Chloro-4-methoxy-phenyl)-3-pyrazin-2-yl-urea

The title compound was prepared from the appropriate reagents, using a procedure
15 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.65(s, 1H);
9.57(s, 1H); 8.99(d, 1H, J=1.5); 8.31(dd, 1H, J=2.7, 1.6) ; 8.25(d, 1H, J=2.5); 7.71(d,
1H, J=2.5); 7.33(dd, 1H, J=8.9, 2.5); 7.12(d, 1H, J=8.9); 3.83(s, 3H). LCMS: method A,
RT= 3.37, [MH⁺=279].


-39-

Example 19**1-(3-Chloro-phenyl)-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.96(s, 1H); 9.78(s, 1H); 9.17(s, 1H); 8.47 (dd, 1H, J=2.5, 1.5); 8.41(d, 1H, J=2.7); 7.90(dd, 1H, J=2.5, 1.5); 7.46-7.49(m, 2H); ;7.21-7.25(m, 1H). method B, RT= 3.31, [MH⁺=249, MNa⁺=271].

Example 20**1-(3-Chloro-phenyl)-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.62(s, 1H); 9.52(s, 1H); 9.04(d, 1H, J=1.5); 8.32 (dd, 1H, J=2.6, 1.5); 8.26(d, 1H, J=2.6) ; 7.20-7.24(m, 2H); 6.99(ddd, 1H, J=8.2, 1, 2.6) ; 6.62(ddd, 1H, J=8.2, 2.6, 1); 3.75(s, 3H). LCMS: method A, RT= 2.67, [MH⁺=245].


Example 21**1-(4-Piperidin-1-yl-phenyl)-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure


-40-

similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.25(s, 1H); 9.20(s, 1H); 8.78(s, 1H); 8.07(dd, 1H, J=2.5, 1.5); 8.00(d, 1H, J=2.7); 7.106(dd, 2H, J=9.0, 2.7); 6.67(dd, 2H, J=9.0, 2.7); 2.83(t, 1H, J=5.3); 1.37-1.42(m, 4H); 1.27-1.31(m, 2H). LCMS: method A, RT= 0.74, 2.28, [MH⁺=203].

5

Example 221-(4-Piperidin-1-yl-phenyl)-3-pyrazin-2-yl-urea


10 The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.49(s, 2H, broad); 9.00(d, 1H, J = 1.46), 8.30(dd, 1H, J = 1.46, 2.56), 8.23(d, 1H, J=2.56), 7.39-7.43 (m, 2H), 6.88-6.93 (m, 2H), 3.73 (s, 3H).

Example 2315 1,3-Di-pyrazin-2-yl-urea


The title compound was prepared from the appropriate reagents, using a procedure similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.41(s, 2H, broad); 9.28(s, 2H), 8.81(dd, 2H, J=2.5, 1.5), 8.47(d, 2H, J=2.56).

20

-41-


Example 24**1-Benzo[1,3]dioxol-5-yl-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure
5 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 9.38(s, 1H, broad), 9.32(s, 1H, broad), 8.8(s, 1H, broad), 8.1(dd, 1H, J = 2.3, 1.5), 8.05 (d, 1H, J = 2.56), 7.05 (d, 1H, J = 2.0), 6.68(d, 1H, J = 8.35); 6.64(dd, 1H, J = 8.3, 2.0), 5.80 (s, 2H).


10 Example 25**1-[5-Chloro-2-(3-dimethylamino-propoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea**

The title compound was prepared from the appropriate reagents, using a procedure
15 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.25(s, 1H, broad); 8.62(s, 1H); 8.31(d, 1H, J=2.2); 8.20(s, 1H, broad); 7.01(d, 1H, J=8.7); 7.04(dd, 1H, J=8.7, 2.2); 4.10(t, 2H, J=6.2); 2.42(s, 3H); 2.40(t, 2H, J=7.3); 2.13(s, 6H); 1.97(td, 2H, J=7.3, 6.2). LCMS: method B, RT= 4.14min, [MH⁺=364].


-42-

Example 26**1-[2-(2-Aziridin-1-yl-ethoxy)-5-chloro-phenyl]-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure
5 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.59 (s, 1H, broad), 8.74 (s, 1H), 8.32 (dd, 1H, J=2.7, 1.5), 8.29 (d, 1H, J=2.56), 8.26 (d, 1H, J = 2.7), 7.10 (d, 1H, J = 8.7), 7.04 (dd, 1H, J = 2.56), 4.20 (t, 2H, J = 5.5), 2.63 (t, 2H, J = 5.5), 1.62 (m, 2H)

10 Example 27**1-[5-Chloro-2-(pyridin-3-ylmethoxy)-phenyl]-3-pyrazin-2-yl-urea**

The title compound was prepared from the appropriate reagents, using a procedure
15 similar to that described in Example 2. ¹H NMR (400 MHz, DMSO-d₆) δ 10.55 (s, 1H, broad), 10.35 (s, 1H), 8.78 (dd, 1H, J = 2.19, 0.54), 8.69 (s, 1H, broad), 8.62 (dd, 1H, J = 1.64, 4.75), 8.32 (d, 1H, J = 2.56), 8.16 (d, 1H, J = 2.74), 7.9 (ddd, 1H, J = 5.5, 4.7, 0.7), 7.61 (s, 1H, broad), 7.48 (ddd, 1H, 7.7, 4.7, 0.7), 7.24 (d, 1H, J = 8.7), 7.08 (dd, 1H, 2.7, 8.7), 5.27 (s, 2H).

Example 281-[5-Chloro-2-amino-propoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea**5 Step 1**[3-(4-Chloro-2-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester

A solution of (3-Hydroxy-propyl)-carbamic acid tert-butyl ester (11mmoles, 1.88ml)
10 in THF(20ml) was added to a suspension of sodium hydride 50% grade (23mmoles,
1.058g) in THF (20ml) and stirred at 50°C for 1 hour. Following cooling to 0°C, 4-
Chloro-1-fluoro-2-nitro-benzene was added and the mixture stirred at RT overnight.
After quenching with water, the organic layer was separated and the aqueous layer
was extracted several times with Ethyl acetate. The combined organic layers were
15 washed with water then brine, and dried over sodium sulfate. The crude reaction was
purified by flash chromatography to afford [3-(4-Chloro-2-nitro-phenoxy)-propyl]-
carbamic acid tert-butyl ester.

NMR: ¹H NMR (400 MHz, DMSO-d₆) δ 8.014(d, 1H, J=2.74) ; 7.71(dd, 1H, J=9.1,
20 2.7); 7.37(d, 1H, J=9.1); 6.85(t, broad, 1H, J=5.8); 4.16(t, 2H, J=6.03); 3.06(td, 2H,
J=5.8, 6.7), 1.85-1.79(m, 2H); 1.36(s, 9H). LCMS: method B, RT= 3.52min,
[MH⁺=331].

-44-

Step 2[3-(2-Amino-4-chloro-phenoxy)-propyl]-carbamic acid tert-butyl ester

A solution of [3-(4-Chloro-2-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester
5 (1.78g) was hydrogenated in ethanol (50ml) in presence of Platinum oxide (178mg)
for 2 hours. The mixture was filtrated over a pad of celite and concentrated under
vacuum. The crude reaction was purified by flash chromatography to afford [3-(2-
Amino-4-chloro-phenoxy)-propyl]-carbamic acid tert-butyl ester (1.39g, yield=86%)
as a viscous oil which solidified slowly:

10

NMR: ¹H NMR (400 MHz, DMSO-d₆) δ 6.80(t, broad, 1H, J=5.4); 6.67(d, 1H,
J=8.4); 6.56(d, 1H, J=2.74); 6.41(dd, 1H, J=8.4, 2.7); 4.92(s, broad, 2H); 3.86(t, 2H,
J=6.2); 3.03(td, 2H, J=5.4, 6.0); 1.79-7.73(m, 2H); 1.31(s, 9H). LCMS: method B,
RT= 3.28min, [MH⁺=301].

15

Step 3(3-{4-Chloro-2-[3-(5-methyl-pyrazin-2-yl)-ureido]-phenoxy}-propyl)-carbamic acid
tert-butyl ester]

20 Using a procedure similar to that described in example 2 step (2 and 3), the desired
urea was obtained as a light beige solid.

¹H NMR (400 MHz, DMSO-d₆) δ: 10.21(s, broad, 1H); 8.41(s, 1H, broad); 8.31-
8.30(m, 1H); 8.17(s, 1H, broad); 7.03-7.029(m, 2H); 6.92-6.91(t, 1H, broad);
4.086(t, 2H, J=6.2); 3.19-3.14(m, 2H); 2.44(s, 3H); 1.92-1.95(m, 2H); 1.36(s, 9H).

25 LCMS: method B, RT= 3.37min, [MH⁺=436].

Step 41-[5-Chloro-2-amino-propoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea

30 A suspension of the urea in dioxane was treated with a 4M HCl Dioxane solution for
1 hour. The solvent was evaporated under vacuum and the residue was triturated with

-45-


a small portion of MeOH and filtrated to afford a light beige solid.

¹H NMR (400 MHz, DMSO-d₆) δ: 10.36(s, 1H); 10.30-10.1(s, 1H, broad); 8.74(s, 1H, broad); 8.296-8.299(m, 1H); 8.05(m, 2H); 7.055-7.052(m, 2H); 4.18(t, 2H, J=6.22); 3.08-3.03(m, 2H), 2.45(s, 3H); 2.19-2.13(m, 2H). LCMS: method B, RT=

5 3.37min, [MH⁺=436].

Example 29

1-[2-(3-Amino-propoxy)-5-chloro-phenyl]-3-pyrazin-2-yl-urea




10

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 28.

¹H NMR (400 MHz, DMSO-d₆) δ: 10.48(s, 1H); 10.38-10.12(s, broad, 1H), 8.84(s, 1H); 8.34(dd, 1H, J=1.64, 1.28); 8.29(m, 1H); 8.27(d, 1H, J=2.7); 8.00(s, broad, 2H); 7.08(m, 2H); 4.18(t, 2H, J=6.2); 3.10-3.00(m, 2H); 2.20-2.10(m, 2H). LCMS: method B, RT= 1.81min, [MH⁺=322].

15

-46-


Example 30**1-[5-Chloro-2-(3-dimethylamino-propoxy)-phenyl]-3-quinoxalin-2-yl-urea**

5

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 1.

1H NMR (400 MHz, DMSO-d₆) δ : 10.29(s, 2H, broad); 10.18(s, 1H, broad); 9.05(s, 1H, broad); 8.30(d, 1H, J=2.5); 8.02(d, 1H, J=8.0); 7.86-7.51(m, 2H); 7.69(dd, 1H, J=8.2, 4.2); 7.16(d, 1H, J=8.7); 7.11(dd, 1H, J=8.7, 2.5); 4.30(t, 2H, J=6.4); 3.23-3.19(m, 2H); 2.66(s, 6H); 2.25-2.18(m, 2H). LCMS: method A, RT= 3.56min, [MH⁺=400].

10

Example 31**1-[2-(3-Amino-propoxy)-5-chloro-phenyl]-3-quinoxalin-2-yl-urea**


20

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 28.

1H NMR (400 MHz, DMSO-d₆) δ : 10.86(s, 2H, Broad); 9.07(s, 1H, broad); 8.34(d, 1H, J=2.5); 8.02(d, 1H, J=8.2); 7.96-7.90(s, 1H, broad); 7.87-7.82(m, 2H); 7.69(ddd, 1H,


-47-

J=8.2, 6, 2.2); 7.17(d, 1H, J=8.7); 7.11(dd, 1H, J=2.5, 8.7); 4.35(t, 2H, J=6.2); 2.96-2.92(m, 2H); 2.12(m, 2H). LCMS: method B, RT= 2.02min, $[MH^+]=372$].

Example 325 1-[2-(2-Amino-ethoxy)-5-chloro-phenyl]-3-pyrazin-2-yl-urea


The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 28

10 1H NMR (400 MHz, DMSO- d_6) δ : 10.66(s, 1H); 9.80(s, 1H); 9.19(d, 1H, J=1.3); 8.47-8.39(s, 2H, broad); 8.33(dd, 1H, J=0.9, 1.6); 8.30(m, 1H); 8.27(d, 1H, J=2.56); 7.05(m, 2H); 4.23(t, 2H, J=5); 3.33-3.31(m, 2H). LCMS: method B, RT= 1.75min, $[MH^+]=308$].

Example 3315 1-[2-(4-Amino-butoxy)-5-chloro-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 28.

20 1H NMR (400 MHz, DMSO- d_6) δ : 10.34(s, 1H); 8.73(s, 1H); 8.31(d, 1H, J=2.4); 8.20(s, 1H); 7.94(s, 2H); 7.09(d, 1H, J=8.8); 7.04(dd, 1H, J=8.8, 2.4); 4.13(t, 2H, J=6.03); 2.93-2.85(m, 2H); 2.46(s, 3H); 1.97-1.90(m, 2H); 1.83-1.78(m, 2H). LCMS: method B, RT= 1.94min, $[MH^+]=349$].

Example 34**1-[5-Chloro-2-amino-propoxy)-phenyl]-3-(6-methoxy-pyrazin-2-yl)-urea**

5


The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 28, the desired urea was obtained as a light beige solid.

1H NMR (400 MHz, DMSO-d₆) δ : 10.31(s, broad, 1H); 9.06(s, 1H); 8.74(s, 1H); 8.21(s, 1H); 8.11(s, 1H, broad); 7.91(m, 2H); 7.031-7.034(m, 2H); 4.15(t, 2H, J=6.04); 3.88(s, 3H); 3.05-3.015(m, 2H); 2.13-2.06(m, 2H). LCMS: method A, RT= 1.94min, [MH⁺=351].

10

Example 35**1-[5-Methyl-2-(3-dimethylamino-propoxy)-phenyl]- 3-pyrazin-2-yl)-urea**

15




The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 1.

1H NMR (400 MHz, DMSO-d₆) δ : 10.32(s, 1H, broad); 10.31(s, 1H, broad); 9.9(s, 1H, broad); 8.82(s, 1H); 8.29-8.27(m, 1H); 8.16(d, 1H, J=2.7); 7.93(m, 1H); 6.86(d, 1H, J=8.2); 6.73(dd, 1H, J=8.2, 2.19); 4.04(t, 2H, J=6.2); 3.24-3.19(m, 2H); 2.71-2.69(d_{app}, 6H); 2.17(s, 3H); 2.20-2.11(m, 2H). LCMS: method B, RT= 3.56min, [MH⁺=330].

20

Example 35A

1-[2-(3-Amino-2,2-dimethyl-propoxy)-5-chloro-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea




5

The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 1. Proton NMR: dH (400 MHz; MeOD) 8.52 (1H, s, CH), 8.16 (1H, s, CH), 7.98 (1H, d, CH), 6.90 (2H, m, 2xCH), 3.78 (2H, s, CH₂), 2.99 (2H, s, CH₂), 2.40 (3H, s, CH₃), 1.09 (6H, s, 2xCH₃). MS: [ES⁺] = 364;

10 [ES⁻] = 362. LCMS: method B.**Example 35B**


6-{3-[2-(3-Amino-propoxy)-5-chloro-phenyl]-ureido}-nicotinamide



15 The title compound was prepared from the appropriate reagents, using a procedure similar to that described in example 1. Proton NMR: dH (400 MHz; MeOD) 8.65 (1H, d, CH), 8.44 (1H, d, CH), 8.16 (1H, d, CH), 7.32 (1H, d, CH), 6.92 (2H, m, 2xCH), 4.10 (2H, t, CH₂), 3.15 (2H, t, CH₂), 2.19 (2H, q, CH₂). MS: [ES⁺] = 364; [ES⁻] = 362. LCMS: method B.

20


-50-

Example 35C1-[2-(3-Amino-propoxy)-5-chloro-phenyl]-3-(5-cyano-pyridin-2-yl)-urea

Proton NMR: dH (400 MHz; DMSO) 10.52 (1H, s, NH), 10.26 (1H, br, NH), 8.53
 5 (1H, d, CH), 8.07 (1H, t, CH), 7.99 (1H, dd, CH), 7.43 (1H, d, CH), 6.87 (2H, d,
 2xCH), 4.00 (2H, t, CH₂), 2.83 (2H, m, CH₂), 1.95 (2H, m, CH₂). MS: [ES⁺] =
 346. LCMS: method B.

Example 35D

10 1-[5-Chloro-2-(3-cyclobutylamino-propoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea



NMR: 1H (400 MHz; DMSO-D₆): 10.15(s, 1H, Broad); 9.1-8.9(2S, 2H,
 broad); 8.56(s, 1H, broad); 8.08(tapp, 1H, J=1.3); 8.05(s, 1H, broad); 6.85(dapp,
 broad); 3.98(t, 2H, J=6.04); 3.52-3.42(m, 1H); 2.85-2.65(m, 2H); 2.25(s, 3H); 2.03-
 15 1.9(m, 6H); 1.613-1.517(m, 2H). LCMS, Method A: Rt= 1.96Min [MH⁺= 390].

LCMS Method A

Analysed using a Waters Symmetry [C8, 50 x 4.6mm, 3.5uM] eluting with
 acetonitrile/water/0.1% formic acid (5-95% acetonitrile) for 5 minutes with a flow rate
 20 of 1.5ml/min.

LCMS Method B

Analysed using a Waters Symmetry [C8, 50 x 4.6mm, 3.5uM] eluting with methanol/water/10mM Ammonium acetate (5-95% methanol) for 5 minutes with a flow rate of 1.5ml/min.

5

NMR

NMR data was recorded on a Bruker NMR spectrometer (400 MHz).

LCMS Method B

10 Analysed using a Waters Symmetry [C8, 50 x 4.6mm, 3.5uM] eluting with methanol/water/10mM Ammonium acetate (5-95% methanol) for 5 minutes with a flow rate of 1.5ml/min.

NMR

15 NMR data was recorded on a Bruker NMR spectrometer (400 MHz).

Example 36 Biological Assays**Chk1 Expression & Purification:**

20 Recombinant human Chk1 was expressed as a fusion protein with glutathione S-transferase at the amino-terminus (GST-Chk1) using standard baculovirus vectors and (Bac-to-Bac®) insect cell expression system purchased from GIBCO™ Invitrogen.

Recombinant protein expressed in insect cells was purified using glutathione
25 sepharose (Amersham Biotech) using standard procedures described by the manufacturer.

Chk1 Fluorescence Polarization Assays:

Chk1 kinase inhibitors were identified using fluorescence polarization to
30 monitor kinase activity. This assay utilized 10 nM GST-Chk1 and contained 5 mM 2-(N-Morpholino)ethanesulfonic acid (MES, pH 6.5), 5 mM magnesium chloride

-52-

(MgCl₂), 0.05% Tween®-20, 1 uM adenosine 5' triphosphate (ATP), 2 mM 1,4-Dithio-DL-threitol (DTT), 1 uM peptide substrate (Biotin-ILSRRPSYRKILND-free acid) (SEQ ID NO: 1), 10 nM peptide substrate tracer (Fluoresceine-GSRRP-pS-YRKI-free acid) (pS = phosphorylated-Serine) (SEQ ID NO: 2), 60 ng anti-phospho-
5 CREB(S133) mouse monoclonal IgG purified on Protein G sepharose from crude mouse ascites purchased from Cell Signaling Technologies (Beverly, MA), 4% dimethyl sulfoxide (DMSO) and 30 uM inhibitor. Reactions were incubated at room temperature for 140 minutes and terminated by addition of 25 mM EDTA (pH 8.0). Stopped reactions were incubated for 120 minutes at room temperature and
10 fluorescence polarization values determined using a Molecular Devices / LJI Biosystems Analyst™ AD (Sunnyvale, CA) with standard fluoresceine settings.

Additonal assays were also used to determine inhibitor potency and ability of inhibitors to compete for ATP binding site of Chk1:

15 **Chk1 SPA filtration Assay:**

Assays (25 ul) contained 10 nM GST-Chk1, 10 mM MES, 2 mM DTT, 10 mM MgCl₂, 0.025% Tween®-20, 1 uM peptide substrate (Biotin-ILSRRPSYRKILND-free acid) (SEQ ID NO: 1), 1 uM ATP, 0.1 uCi ³³P-γ -ATP (New England Nuclear, NEN) and reacted for 90 minutes at room temperature.
20 Reactions were terminated by adding 55 ul of phosphate buffered saline containing 50 mM EDTA, 6.9 mM ATP, 0.5 mg Scintillation proximity assay (SPA) beads (Amersham Biosciences). Peptide substrate was allowed to bind beads for 10 minutes at room temperature followed by filtration on a Packard GF/B Unifilter plate and washing with phosphate buffered saline. Dried plates were sealed with
25 Topseal™ (NEN) and ³³P incorporated to peptide substrate detected using a Packard Topcount® scintillation counter with standard settings for ³³P.

Chk1 FlashPlate® kinase assay:

Assays (25 ul) contained 8.7 nM GST-Chk1, 10 mM MES, 0.1 mM ethylene
30 glycol-bis(β-aminoethylether)-N,N,N',N'-tetracetic acid (EGTA, pH 8.0), 2 mM

DTT, 0.05% Tween 20, 3 uM peptide substrate (Biotin-ILSRRPSYRKILND-free acid) (SEQ ID NO: 1), 1 uM ATP, 0.4 uCi ^{33}P - γ -ATP (NEN), 4% DMSO.

Reactions were incubated for 30 minutes at room temperature, terminated with 50 ul of 50 mM EDTA and 90 ul were transferred to streptavidin-coated FlashPlates® (NEN) and incubated for 1 hour at room temperature. Plates were washed with phosphate buffered saline containing 0.01% Tween-20 and 10 mM sodium pyrophosphate. Plates were dried, sealed with Topseal™ (NEN) and amount of ^{33}P incorporated into the peptide substrate measure using a Packard Topcount® NXT™ scintillation counter with standard settings.

10

Chk1 DELFIA® kinase assay:

Assays (25 ul) utilized 6.4 nM GST-Chk1 containing 25 mM Tris, pH 8.5, 20% glycerol, 50 mM sodium chloride (NaCl), 0.1% Surfact-Amps® 20, 1 uM peptide substrate (Biotin-GLYRSPSPEN-amide) (SEQ ID NO: 3), 2 mM DTT, 4% DMSO, 12.5 uM ATP, 5 mM MgCl_2 and reacted for 30 minutes at room temperature. Reactions were terminated with 100 ul of Stop buffer containing 1% BSA, 10 mM Tris, pH 8.0, 150 mM NaCl, 100 mM EDTA. Stopped reactions (100 ul) were transferred to 96 well neutravidin plates (Pierce) to capture the biotin-peptide substrate during a 30 minute room temperature incubation. Wells were washed and reacted with 100 ul PerkinElmer Wallac Assay Buffer containing 21.5 ng/ml anti-phospho-Ser216-Cdc25c rabbit polyclonal antibody from Cell Signaling Technology (Beverly, MA) and 292ng/ml europium labeled anti-rabbit-IgG for 1 hour at room temperature. Wells were washed and europium released from the bound antibody by addition of Enhancement Solution (100 ul) (PerkinElmer Wallac) and detected using a Wallac Victor2™ using standard manufacturer settings.

20

25

Example 37 Compounds of the Present Invention are Potent Inhibitors of CHK-1

Compounds of the present invention were tested in the Chk1 FlashPlate® kinase assay described above. The results are shown in Table 1 below.

30

Table 1

	<u>Compound</u>	<u>IC₅₀</u>
	Compound from Example 1	A
5	Compound from Example 2	A
	Compound from Example 3	A
	Compound from Example 4	A
	Compound from Example 5	B
	Compound from Example 6	B
10	Compound from Example 7	B
	Compound from Example 8	B
	Compound from Example 9	B
	Compound from Example 10	B
	Compound from Example 11	B
15	Compound from Example 12	B
	Compound from Example 13	B
	Compound from Example 14	B
	Compound from Example 15	B
	Compound from Example 16	C
20	Compound from Example 17	C
	Compound from Example 18	C
	Compound from Example 19	C
	Compound from Example 20	C
	Compound from Example 21	C
25	Compound from Example 22	C
	Compound from Example 23	C
	Compound from Example 24	C
	Compound from Example 25	A
	Compound from Example 26	B
30	Compound from Example 27	B
	Compound 46	B

-55-

	Compound 92	A
	Compound 109	A
	Compound 110	A
	Compound 111	A
5	Compound 112	A

A = IC₅₀ less than 0.1 μ M

B = IC₅₀ less than 1.0 μ M

C = IC₅₀ less than 20.0 μ M

10

As can be seen from the data presented in the Table, the disclosed compounds are potent inhibitors of Chk-1.

Example 38 WST Assay Procedure

15 HT29, HCT116 (5000 cells/well) or other cells were seeded (75 μ l) to 96 well clear bottom plates at densities which provide linear growth curves for 72 hours. Cells were cultured under sterile conditions in appropriate media and for HT29 & HCT116 this media was McCoy's 5A containing 10% Fetal Bovine Serum (FBS). Following the initial seeding of cells they are incubated at 37°C, 5% CO₂

20 from 17 to 24 hours at which time the appropriate DNA damaging agents (camptothecins, 5-fluorouracil and etoposid) are added at increasing concentrations to a point which is capable of causing at least 80% cell killing with in 48 hours. Final volume of all DNA damaging agent & compound additions was 25 μ l and assays contained <1 % DMSO final. At the same time as DNA Damaging agent

25 addition, Chk1 inhibitor was added at fixed concentrations to each DNA damaging agent titration to observe enhancement of cell killing. In addition, toxicity of each Chk1 inhibitor alone was observed. By doing this over a range of Chk1 inhibitor concentrations we were able to identify compounds which maximally enhance (2-30 fold) cell killing by each DNA damaging agent and generated \leq 80% cell killing by

30 the compound alone. Cell viability/cell killing under the conditions described above

was determined by addition WST reagent (Roche) according to the manufacturer at 47 hours following DNA damage & Chk1 inhibitor addition and following a 3.5 hour or 2.5 hour incubation at 37C, 5% CO₂, OD₄₅₀ was measured. The results from these experiments are shown below in Table 2.

5

Table 2

Example	R ¹	IC ₅₀ average	Shift					
			78nM	156nM	313nM	625nM	1.25μM	2.5μM
30	-O(-CH ₂) ₃ N(CH ₃) ₂	0.019	nd	nd	nd	nd	1	1.4
31	-O(CH ₂) ₃ NH ₂	0.005	nd	1.3	1.8	2.8	4.4	6.2
2	-O(CH ₂) ₂ N(CH ₃) ₂	0.008	nd	1	1.1	1.5	1.9	2.6
32	-O(CH ₂) ₂ NH ₂	0.016	nd	nd	nd	nd	1.2	1.4
25	-O(CH ₂) ₃ N(CH ₃) ₂	0.0045	nd	1.1	1.7	2.5	3.3	4.4
28	-O(CH ₂) ₃ NH ₂	0.004	2.7	3.4	5.3	6.8	toxic	toxic
1	-O(CH ₂) ₃ N(CH ₃) ₂	0.0035	nd	1	1.2	1.6	2.2	3.4
29	-O(CH ₂) ₃ NH ₂	0.0025	2.5	3.1	4.5	5.0	toxic	toxic
33	-O(CH ₂) ₄ NH ₂	0.003	1.8	2.4	2.7	3.1	toxic	toxic
35	O-(CH ₂) ₃ N(CH ₃) ₂	0.016	nd	nd	nd	nd	2.1	2.9
34	-O(CH ₂) ₃ NH ₂	0.020	nd	nd	nd	nd	2.4	3.031

Where a shift of 1 is equal to no shift.

10 Nd = not determined.

* IC₅₀ μM for the test compound versus CHK-1

As can be seen from these datas, phenyl urea CHK-1 inhibitors substituted with an -O-T-NH₂ group significantly enhance of the activity of the DNA damaging agent compared with other phenyl urea CHK-1 inhibitors.

15 While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.


CLAIMS

What is claimed is:

5

1. A method of inhibiting Chk-1 in a subject in need of such inhibition comprising administering to the subject an effective amount of a compound of Formula III:

10



III

or a pharmaceutically acceptable salt thereof, wherein:

15

N;

X₄ is CH or N;

Z is O, S, or N-CN;

Ring A is optionally substituted at any substitutable carbon by R⁴;

R¹ is -T-NH₂, -V-T-NH₂, -T-NHR^x, -V-T-NHR^x;

20

T is a C₁₋₆ straight or branched alkylidene chain that is optionally interrupted by -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, or -N(R⁵)SO₂-, wherein the alkylidene chain or a portion thereof is optionally part of a 3-6 membered ring system;

25

-58-

V is $-O-$, $-S-$, $-N(R^5)-$, $-S(O)-$, $-SO_2-$, $-C(O)-$, $-OC(O)-$, $-N(R^5)C(O)-$, $-C(O)N(R^5)-$, $-SO_2N(R^5)-$, or $-N(R^5)SO_2-$;

R^2 and R^3 are each independently selected from hydrogen, C_{1-6} alkyl optionally substituted with $-N(R^8)_2$, $-C(=O)R$, $-CO_2R$, or SO_2R , or R^2 and R^3 taken together with their intervening atoms form an optionally substituted an optionally substituted 5-6 membered ring;

each R^4 is independently selected from halo, $-OR$, $-SR$, $-CN$, $-NO_2$, $-N(R^5)_2$, $-N(R^5)C(O)R$, $-N(R^5)CO_2R$, $-N(R^5)C(O)N(R^5)_2$, $-C(O)N(R^5)_2$, $-C(O)R^5$, $-OC(O)N(R^5)_2$, $-CO_2R$, $-SO_2R$, $-S(O)R$, $-SO_2N(R^5)_2$, $-N(R^5)SO_2R$, or an optionally substituted group selected from C_{1-8} aliphatic, aryl, aralkyl, heterocyclyl, heterocyclealkyl, heteroaryl, or heteroaralkyl, or two *ortho* R^4 s, taken together with the *ortho* carbon atoms to which they are bonded, form an optionally substituted five or six membered phenyl, pyridyl or heterocyclyl fused to Ring A;

each R^5 is independently selected from hydrogen, C_{1-6} aliphatic, $-CO_2R$, $-SO_2R$, or $-C(O)R$, or two R^5 on the same nitrogen taken together with the nitrogen form a 5-8 membered heteroaryl or heterocycle ring having 1-4 heteroatoms selected from N, O, or S;

each R^8 is independently a C_{1-3} alkyl or, taken together with the nitrogen atom to which they are bonded, a 5-7 membered nitrogen containing heterocycle;


Ring D is optionally substituted by C_{1-4} aliphatic or haloaliphatic, $-OR^7$, $-SR^7$, $-C(O)R^7$, $-CO_2R^7$, $-SO_2R^7$, $-CN$, $-C(O)N(R^7)_2$, $-N(R^7)C(O)(C_{1-2}$ alkyl), or $-N(R^7)_2$ and is optionally fused to an optionally substituted phenyl or optionally substituted cyclohexyl ring;

each R^7 is independently selected from hydrogen or an optionally substituted C_{1-3} aliphatic or $-N(R^7)_2$ is a nitrogen-containing heterocyclyl;

each R is independently selected from hydrogen or an optionally substituted group selected from C_{1-6} aliphatic, aryl, aralkyl, heteroaryl, or heteroaralkyl –butyl; and

R^x is $C1-C8$ alkyl.

2. The method of Claim 1 wherein X_4 is N.
3. The method of Claim 2 wherein: i) X_1 is N and X_2 and X_3 are CH; X_2 is N and X_1 and X_3 are CH; X_3 is N and X_1 and X_2 are CH; or X_1 - X_3 are CH; and
 5 ii) Ring A is optionally substituted at any substitutable carbon by R^4 .
4. The method of Claim 3 wherein R^2 and R^3 are each hydrogen, and Z is oxygen.
5. The method of Claim 4 wherein X_1 - X_3 are CH and Ring A is optionally substituted at any substitutable carbon by R^4 .
6. The method of Claim 5 wherein V is $-O-$ and T is C_{2-5} alkylidene.
7. The method of Claim 6 wherein the compound is represented by the
 10 following structural formula:



20 wherein:

R^4 is $-F$, $-Cl$, $-Br$, $-I$, $-COOR^a$, $-NHCOR^a$, $-CF_3$, $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-N(R^a)_2$, $-CH_2N(R^a)_2$, $-CH_2CH_2N(R^a)_2$, piperidinyl, morpholinyl and pyrrolidinyl;

R^a is $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2NH_2$, $-CH_2CH_2NH(CH_3)$, $-CH_2CH_2N(CH_3)_2$, $-CH_2CH_2(N\text{-morpholinyl})$, $-CH_2CH_2(N\text{-piperidinyl})$ or

25


-60-

-CH₂CH₂(*N*-pyrrolidinyl); and

Ring **D** is optionally monosubstituted at the position *meta* or *para* to the carbon atom bonded to the urea nitrogen with methyl, -OCH₃, or -NH₂, and is optionally fused to a phenyl or cyclohexyl ring.

5

8. The method of Claim 6 wherein the compound is represented by the following structural formula:



10

wherein:

R⁴ is -F, -Cl, -Br, -I, -COOR^a, -NHCOR^a, -CF₃, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -N(R^a)₂, -CH₂N(R^a)₂, -CH₂CH₂N(R^a)₂, piperidinyl, morpholinyl and pyrrolidinyl;

15

R^a is -CH₃, -CH₂CH₃, -CH₂CH₂NH₂, -CH₂CH₂NH(CH₃), -CH₂CH₂N(CH₃)₂, -CH₂CH₂(*N*-morpholinyl), -CH₂CH₂(*N*-piperidinyl) or -CH₂CH₂(*N*-pyrrolidinyl); and


Ring **D** is optionally monosubstituted at the position *para* to the carbon atom bonded to the urea nitrogen with -CO₂R⁷, -CN or -C(O)N(R⁷)₂.

20

9. The method of Claim 6 wherein R¹ is -(C₂₋₅ alkylidene)-NH₂ or -O-(C₂₋₅ alkylidene)-NH₂.

-61-

10. The method of Claim 1 wherein the compound is represented by the following structural formula:



wherein:

5

V is $-O-$ and T is C_2-C_5 alkylidene;

R^4 is $-F$, $-Cl$, $-Br$, $-I$, $-COOR^a$, $-NHCOR^a$, $-CF_3$, $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-N(R^a)_2$, $-CH_2N(R^a)_2$, $-CH_2CH_2N(R^a)_2$, piperidinyl, morpholinyl and pyrrolidinyl;

10



R^a is $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2NH_2$, $-CH_2CH_2NH(CH_3)$, $-CH_2CH_2N(CH_3)_2$, $-CH_2CH_2(N\text{-morpholinyl})$, $-CH_2CH_2(N\text{-piperidinyl})$ or $-CH_2CH_2(N\text{-pyrrolidinyl})$; and

Ring **D** is optionally monosubstituted at the position *para* to the carbon atom bonded to the urea nitrogen with $-CO_2R^7$, $-CN$ or $-C(O)N(R^7)_2$.


15

-62-

11. A method of inhibiting Chk-1 in a subject in need of such inhibition comprising administering to the subject an effective amount of a compound represented by a structural formula selected from:




5



or a pharmaceutically acceptable salt thereof.

-63-

12. A method of inhibiting Chk-1 in a subject in need of such inhibition comprising administering to the subject an effective amount of a compound selected from the group consisting of:




5


or a pharmaceutically acceptable salt thereof.

-64-


13. A method of inhibiting Chk-1 in a subject in need of such inhibition comprising administering to the subject an effective amount of a compound selected from the group consisting of:




;



;




; and



;

or a pharmaceutically acceptable salt thereof.

14. A method of treating cancer in a subject comprising administering to the subject an effective amount of a compound of Formula III:



III

or a pharmaceutically acceptable salt thereof, wherein:

X_1 - X_3 are independently CH or N, that provided that X_1 - X_3 are not all

N;

-65-

X₄ is CH or N;

Z is O, S, or N-CN;

Ring A is optionally substituted at any substitutable carbon by R⁴;

R¹ is -T-NH₂, -V-T-NH₂, -T-NHR^x, -V-T-NHR^x;

5 T is a C₁₋₆ straight or branched alkylidene chain that is optionally interrupted by -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, or -N(R⁵)SO₂-, wherein the alkylidene chain or a portion thereof is optionally part of a 3-6 membered ring system;

10 V is -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, or -N(R⁵)SO₂-;

 R² and R³ are each independently selected from hydrogen, C₁₋₆ alkyl optionally substituted with -N(R⁸)₂, -C(=O)R, -CO₂R, or SO₂R, or R² and R³ taken together with their intervening atoms form an optionally substituted an optionally substituted 5-6 membered ring;

15 each R⁴ is independently selected from halo, -OR, -SR, -CN, -NO₂, -N(R⁵)₂, -N(R⁵)C(O)R, -N(R⁵)CO₂R, -N(R⁵)C(O)N(R⁵)₂, -C(O)N(R⁵)₂, -C(O)R⁵, -OC(O)N(R⁵)₂, -CO₂R, -SO₂R, -S(O)R, -SO₂N(R⁵)₂, -N(R⁵)SO₂R, or an optionally substituted group selected from C₁₋₈ aliphatic, aryl, aralkyl, heterocyclyl, heterocyclealkyl, heteroaryl, or heteroaralkyl, or two *ortho* R⁴s, taken together with the *ortho* carbon atoms to which they are bonded, form an optionally substituted five or six membered phenyl, pyridyl or heterocyclyl fused to Ring A;

20 each R⁵ is independently selected from hydrogen, C₁₋₆ aliphatic, -CO₂R, -SO₂R, or -C(O)R, or two R⁵ on the same nitrogen taken together with the nitrogen form a 5-8 membered heteroaryl or heterocycle ring having 1-4 heteroatoms selected from N, O, or S;

25 each R⁸ is independently a C₁₋₃ alkyl or, taken together with the nitrogen atom to which they are bonded, a 5-7 membered nitrogen containing heterocycle;

30

Ring **D** is optionally substituted by C₁₋₄ aliphatic or haloaliphatic, -OR⁷, -SR⁷, -C(O)R⁷, -CO₂R⁷, -SO₂R⁷, -CN, -C(O)N(R⁷)₂, -N(R⁷)C(O)(C₁₋₂ alkyl), or -N(R⁷)₂ and is optionally fused to an optionally substituted phenyl or optionally substituted cyclohexyl ring;

5 each R⁷ is independently selected from hydrogen or an optionally substituted C₁₋₃ aliphatic or -N(R⁷)₂ is a nitrogen-containing heterocyclyl;

 each R is independently selected from hydrogen or an optionally substituted group selected from C₁₋₆ aliphatic, aryl, aralkyl, heteroaryl, or heteroaralkyl -butyl; and

10 R^x is C1-C8 alkyl.

15. The method of Claim 14 wherein X₄ is N.

16. The method of Claim 15 wherein the compound is co-administered with a
15 DNA-damaging anti-cancer drug and/or radiation therapy.

17. The method of Claim 16 wherein the cancer is mult-drug resistant.

18. The method of Claim 15 wherein the cancer is characterized by upregulation
20 of Chk-1 protein or Chk-1 protein activity.

19. The method of Claim 15 wherein: i) X₁ is N and X₂ and X₃ are CH; X₂ is N
 and X₁ and X₃ are CH; X₃ is N and X₁ and X₂ are CH; or X₁-X₃ are CH; and
 ii) Ring A is optionally substituted at any substitutable carbon by R⁴.


25

20. The method of Claim 19 wherein R² and R³ are each hydrogen, and Z is
 oxygen.

21. The method of Claim 20 wherein X₁-X₃ are CH and Ring A is optionally
30 substituted at any substitutable carbon by R⁴.

22. The method of Claim 21 wherein V is —O— and T is C₂₋₅ alkylidene.

23. The method of Claim 22 wherein the compound is represented by the
5 following structural formula:



wherein:

R⁴ is —F, —Cl, —Br, —I, —COOR^a, —NHCOR^a, —CF₃, —CH₃, —CH₂CH₃,
10 —CH(CH₃)₂, —N(R^a)₂, —CH₂N(R^a)₂, —CH₂CH₂N(R^a)₂, piperidinyl, morpholinyl
and pyrrolidinyl;


R^a is —CH₃, —CH₂CH₃, —CH₂CH₂NH₂, —CH₂CH₂NH(CH₃),
—CH₂CH₂N(CH₃)₂, —CH₂CH₂(N-morpholinyl), —CH₂CH₂(N-piperidinyl) or
—CH₂CH₂(N-pyrrolidinyl); and

15 Ring D is optionally monosubstituted at the position *meta* or *para* to
the carbon atom bonded to the urea nitrogen with methyl, —OCH₃, or —NH₂,
and is optionally fused to a phenyl or cyclohexyl ring.


24. The method of Claim 22 wherein R¹ is —(C₂₋₅ alkylidene)—NH₂ or —O—(C₂₋₅
20 alkylidene)—NH₂.

-68-


25. A method of treating cancer in a subject comprising administering to the subject an effective amount of a compound represented by a structural formula selected from:




;



;



; or




;

or a pharmaceutically acceptable salt thereof.


-69-

26. A method of treating cancer 1 in a subject comprising administering to the subject an effective amount of a compound represented by a structural formula selected from:



or a pharmaceutically acceptable salt thereof.

27. A compound of Formula III:



III

or a pharmaceutically acceptable salt thereof, wherein:

X_1 - X_3 are independently CH or N, that provided that X_1 - X_3 are not all

N;

X₄ is CH or N;

Z is O, S, or N-CN;

Ring A is optionally substituted at any substitutable carbon by R⁴;

5 R¹ is -T-NH₂, -V-T-NH₂, -T-NHR^x, -V-T-NHR^x;

T is a C₁₋₆ straight or branched alkylidene chain that is optionally interrupted by -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, or -N(R⁵)SO₂-, wherein the alkylidene chain or a portion thereof is optionally part of a 3-6 membered ring system;

V is -O-, -S-, -N(R⁵)-, -S(O)-, -SO₂-, -C(O)-, -OC(O)-, -N(R⁵)C(O)-, -C(O)N(R⁵)-, -SO₂N(R⁵)-, or -N(R⁵)SO₂-;

R² and R³ are each independently selected from hydrogen, C₁₋₆ alkyl optionally substituted with -N(R⁸)₂, -C(=O)R, -CO₂R, or SO₂R, or R² and R³ taken together with their intervening atoms form an optionally substituted an optionally substituted 5-6 membered ring;

each R⁴ is independently selected from halo, -OR, -SR, -CN, -NO₂, -N(R⁵)₂, -N(R⁵)C(O)R, -N(R⁵)CO₂R, -N(R⁵)C(O)N(R⁵)₂, -C(O)N(R⁵)₂, -C(O)R⁵, -OC(O)N(R⁵)₂, -CO₂R, -SO₂R, -S(O)R, -SO₂N(R⁵)₂, -N(R⁵)SO₂R, or an optionally substituted group selected from C₁₋₈ aliphatic, aryl, aralkyl, heterocyclyl, heterocyclealkyl, heteroaryl, or heteroaralkyl, or two *ortho* R⁴s, taken together with the *ortho* carbon atoms to which they are bonded, form an optionally substituted five or six membered phenyl, pyridyl or heterocyclyl fused to Ring A;

25 each R⁵ is independently selected from hydrogen, C₁₋₆ aliphatic, -CO₂R, -SO₂R, or -C(O)R, or two R⁵ on the same nitrogen taken together with the nitrogen form a 5-8 membered heteroaryl or heterocycle ring having 1-4 heteroatoms selected from N, O, or S;

30 each R⁸ is independently a C₁₋₃ alkyl or, taken together with the nitrogen atom to which they are bonded, a 5-7 membered nitrogen containing heterocycle;

-71-

Ring **D** is optionally substituted by C₁₋₄ aliphatic or haloaliphatic, -OR⁷, -SR⁷, -C(O)R⁷, -CO₂R⁷, -SO₂R⁷, -CN, -C(O)N(R⁷)₂, -N(R⁷)C(O)(C₁₋₂ alkyl), or -N(R⁷)₂ and is optionally fused to an optionally substituted phenyl or optionally substituted cyclohexyl ring;

5 each R⁷ is independently selected from hydrogen or an optionally substituted C₁₋₃ aliphatic or -N(R⁷)₂ is a nitrogen-containing heterocyclyl;

 each R is independently selected from hydrogen or an optionally substituted group selected from C₁₋₆ aliphatic, aryl, aralkyl, heteroaryl, or heteroaralkyl -butyl; and

10 R^x is C1-C8 alkyl.

28. The compound of Claim 27 wherein X₄ is N.

29. The compound of Claim 28 wherein: i) X₁ is N and X₂ and X₃ are CH; X₂ is
15 N and X₁ and X₃ are CH; X₃ is N and X₁ and X₂ are CH; or X₁-X₃ are CH;
and ii) Ring A is optionally substituted at any substitutable carbon by R⁴.

30. The compound of Claim 29 wherein R² and R³ are each hydrogen, and Z is
oxygen.

20


31. The compound of Claim 30 wherein X₁-X₃ are CH and Ring A is optionally
substituted at any substitutable carbon by R⁴.

32. The compound of Claim 31 wherein V is -O- and T is C₂₋₅ alkylidene.

25

-72-

33. The compound of Claim 32 wherein the compound is represented by the following structural formula:




wherein:

- 5 R^4 is -F, -Cl, -Br, -I, -COOR^a, -NHCOR^a, -CF₃, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -N(R^a)₂, -CH₂N(R^a)₂, -CH₂CH₂N(R^a)₂, piperidinyl, morpholinyl and pyrrolidinyl;

- R^a is -CH₃, -CH₂CH₃, -CH₂CH₂NH₂, -CH₂CH₂NH(CH₃), -CH₂CH₂N(CH₃)₂, -CH₂CH₂(*N*-morpholinyl), -CH₂CH₂(*N*-piperidinyl) or
10 -CH₂CH₂(*N*-pyrrolidinyl); and

Ring **D** is optionally monosubstituted at the position *meta* or *para* to the carbon atom bonded to the urea nitrogen with methyl, -OCH₃, or -NH₂ and is optionally fused to a phenyl or cyclohexyl ring.

- 15 34. The compound of Claim 32 wherein the compound is represented by the following structural formula:



wherein:

- R^4 is -F, -Cl, -Br, -I, -COOR^a, -NHCOR^a, -CF₃, -CH₃, -CH₂CH₃,
20 -CH(CH₃)₂, -N(R^a)₂, -CH₂N(R^a)₂, -CH₂CH₂N(R^a)₂, piperidinyl, morpholinyl

-73-

and pyrrolidinyl;


R^a is $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{CH}_2\text{NH}(\text{CH}_3)$,
 $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, $-\text{CH}_2\text{CH}_2(N\text{-morpholinyl})$, $-\text{CH}_2\text{CH}_2(N\text{-piperidinyl})$ or
 $-\text{CH}_2\text{CH}_2(N\text{-pyrrolidinyl})$; and

5 Ring **D** is optionally monosubstituted at the position *para* to the
carbon atom bonded to the urea nitrogen with $-\text{CO}_2\text{R}^7$, $-\text{CN}$ or $-\text{C}(\text{O})\text{N}(\text{R}^7)_2$.

35. The compound of Claim 32 wherein R^1 is $-(\text{C}_{2-5} \text{ alkylidene})-\text{NH}_2$ or $-\text{O}-(\text{C}_{2-5}$
alkylidene)- NH_2 .

10

36. The compound of Claim 27 wherein the compound is represented by the
following structural formula:



15

wherein:

R^4 is $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{COOR}^a$, $-\text{NHCOR}^a$, $-\text{CF}_3$, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$,
 $-\text{CH}(\text{CH}_3)_2$, $-\text{N}(\text{R}^a)_2$, $-\text{CH}_2\text{N}(\text{R}^a)_2$, $-\text{CH}_2\text{CH}_2\text{N}(\text{R}^a)_2$, piperidinyl, morpholinyl
and pyrrolidinyl;

20


R^a is $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{CH}_2\text{NH}(\text{CH}_3)$,
 $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, $-\text{CH}_2\text{CH}_2(N\text{-morpholinyl})$, $-\text{CH}_2\text{CH}_2(N\text{-piperidinyl})$ or
 $-\text{CH}_2\text{CH}_2(N\text{-pyrrolidinyl})$; and

Ring **D** is optionally monosubstituted at the position *para* to the
carbon atom bonded to the urea nitrogen with $-\text{CO}_2\text{R}^7$, $-\text{CN}$ or $-\text{C}(\text{O})\text{N}(\text{R}^7)_2$.

25

-74-


37. A compound represented by a structural formula selected from:



or a pharmaceutically acceptable salt thereof.

-75-


38. A compound represented by a structural formula selected from the group consisting of:




5 or a pharmaceutically acceptable salt thereof.

-76-


39. A compound selected from the group consisting of:




;



;



; and




;

5 or a pharmaceutically acceptable salt thereof.

40. A pharmaceutical composition comprising the compound of Claim 27 and a pharmaceutically acceptable carrier.

10 41. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

15 X is CR¹;
X₁-X₃ are CH;
Z is O;

-77-

Ring A is optionally substituted at any substitutable carbon by R^4 ;

R^1 is V-T- R^6 ;

T is a C_{2-4} alkylidene chain;

V is -O-;


5 R^2 and R^3 are each hydrogen;

each R^4 is independently selected from halo, -OR, -SR, -CN, -NO₂,
 $-N(R^5)_2$, $-N(R^5)C(O)R$, $-N(R^5)CO_2R$, $-N(R^5)C(O)N(R^5)_2$, $-C(O)N(R^5)_2$,
 $-OC(O)N(R^5)_2$, $-CO_2R$, $-SO_2R$, $-S(O)R$, $-SO_2N(R^5)_2$, $-N(R^5)SO_2R$, or an
 10 optionally substituted group selected from C_{1-8} aliphatic, aryl, aralkyl,
 heterocyclyl, heterocyclealkyl, heteroaryl, or heteroaralkyl, or two *ortho* R^4 s,
 taken together with the *ortho* carbon atoms to which they are bonded, form
 an optionally substituted five or six membered phenyl, pyridyl or
 heterocyclyl fused to Ring A;

each R^5 is independently selected from hydrogen, C_{1-6} aliphatic, -
 15 CO_2R , $-SO_2R$, or $-C(O)R$, or two R^5 s on the same nitrogen taken together
 with the nitrogen form a 5-8 membered heteroaryl or heterocycle ring having
 1-4 heteroatoms selected from N, O, or S;

R^6 -NH₂;

each R^8 is independently a C_{1-3} alkyl or, taken together with the
 20 nitrogen atom to which they are bonded, a 5-7 membered nitrogen containing
 heterocycle;



Y_{1-4} are each independently selected from CH or nitrogen, provided
 that Ring B has no more than three nitrogen atoms and Y_1 and Y_2 are not
 25 both N, said Ring B being optionally substituted by C_{1-4} aliphatic or
 haloaliphatic, -OR⁷, -SR⁷, -C(O)R⁷, -CO₂R⁷, -SO₂R⁷, -CN, -C(O)N(R⁷)₂, -
 $N(R^7)C(O)(C_{1-2} \text{ alkyl})$, or -N(R⁷)₂;

each R^7 is independently selected from hydrogen or an optionally

-78-

substituted C₁₋₃ aliphatic or -N(R⁷)₂ is a nitrogen-containing heterocyclyl; and
each R is hydrogen.

42. A pharmaceutical composition comprising the compound of Claim 41 and a
5 pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/16677

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/17 A61K31/395 A61P35/00 C07D401/12 C07D213/04
C07D241/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 02 070494 A (ICOS CORP) 12 September 2002 (2002-09-12) claims; examples -----	1-42
Y	EP 1 153 920 A (KIRIN BREWERY) 14 November 2001 (2001-11-14) page 2, paragraph 3 - page 3, paragraph 3; claims; examples 15-17,20,21,27-29,33-35,44,71,83,87 -----	1-42
Y	EP 1 199 306 A (BANYU PHARMA CO LTD) 24 April 2002 (2002-04-24) page 240, paragraph 1149; claims; examples; tables 4-70 ----- -/--	1-42



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

16 September 2003

Date of mailing of the international search report

25/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Winger, R.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/16677

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>JACKSON J R ET AL: "An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage"</p> <p>CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 566-572, XP002959445</p> <p>ISSN: 0008-5472</p> <p>the whole document</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/16677

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/16677

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02070494	A	12-09-2002	WO 02070494 A1	12-09-2002
			US 2003069284 A1	10-04-2003
EP 1153920	A	14-11-2001	AU 3074800 A	07-08-2000
			BR 0007656 A	30-10-2001
			CA 2361057 A1	27-07-2000
			EP 1153920 A1	14-11-2001
			NO 20012617 A	14-09-2001
			CN 1344254 T	10-04-2002
			HU 0105133 A2	29-07-2002
			WO 0043366 A1	27-07-2000
			PL 349036 A1	01-07-2002
			TR 200102090 T2	21-01-2002
EP 1199306	A	24-04-2002	AU 6314900 A	13-02-2001
			CA 2380389 A1	01-02-2001
			EP 1199306 A1	24-04-2002
			WO 0107411 A1	01-02-2001
			JP 2001106673 A	17-04-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.